Document:

EX-4.4

 Exhibit 4.4 

SECOND AMENDED AND RESTATED AGENCY AGREEMENT 

January 5, 2018 
 ESSA Pharma Inc. 

999 West Broadway, Suite 720 
 Vancouver, British Columbia V5Z 1K5

 Attention: David Parkinson, Chief Executive Officer 

Dear Sir: 
 ESSA Pharma Inc. (the
“Corporation”) and Bloom Burton Securities Inc. (the “Agent”) are parties to an amended and restated agency agreement dated January 2, 2018 (the “Original A&R Agreement”). The Corporation
and the Agents have agreed to amend and restate the Original A&R Agreement in its entirety, so that the respective duties, rights, and obligations of the parties with respect to each other and to the Offering (as defined herein), shall be
governed by this Agreement (as defined herein). 
 The Agent understands that the Corporation proposes to issue and sell up to 125,000,000 Common Shares (as
defined herein) (the “Offered Shares”) at a purchase price of US$0.20 per Offered Share (the “Offering Price”) for aggregate gross proceeds of up to US$25 million. In lieu of an Offered Share, purchasers may
elect to purchase one pre-funded Common Share purchase warrant (a “Warrant”) at the Offering Price. Each Warrant will entitle the holder thereof to acquire, subject to adjustment in certain
circumstances, one Common Share (a “Warrant Share”) until 4:30 p.m. (Toronto time) on the date that is 60 months following the issuance date thereof. The exercise price of the Warrants will be
pre-funded except for a nominal exercise price of US$0.0001 per Warrant Share. The Agent also understands and acknowledges that the Corporation will complete the Concurrent Offering (as defined herein)
contemporaneously with the closing of the first tranche of the Offering.  
 In addition, the Corporation hereby grants to the Agent an option (the
“Over-Allotment Option”), exercisable in whole or in part, subject to approval by the Corporation, at any time and from time to time up to January 17, 2018, to arrange for the purchase from the Corporation of up to that number
of additional Offered Shares (the “Additional Shares”) or Warrants (the “Additional Warrants” and together with the Additional Shares, the “Additional Securities”) as is equal to 15% of the Offered
Securities (as defined herein) issued on the Closing Date (as defined herein) on the same basis as the Offered Securities to cover the Agent’s over-allocation position, if any, and for market stabilization purposes. Unless otherwise
specifically referenced or unless the context otherwise requires, all references to: (i) “Offered Shares” shall include the Additional Shares; (ii) “Warrants” shall include the Additional Warrants; and (iii) “Offered
Securities” shall include the Additional Securities. If the Agent elects to exercise the Over-Allotment Option, the Agent shall notify the Corporation in writing not later than January 17, 2018, which notice shall specify the number of
Additional Securities requested to be sold under the Offering (as defined herein) pursuant to the exercise of the Over-Allotment Option and the date upon which such Additional Securities would be purchased (the “Over-Allotment Option Closing
Date”). The Corporation shall notify the Agent in writing not later than two Business Days (as defined herein) following receipt of the Agent’s notice of exercise as to whether the Corporation approves the exercise of the
Over-Allotment Option and shall confirm the Over-Allotment Option Closing Date if so approved. Such date may be the same as the Closing Date, but otherwise not earlier than the date of the Corporation’s notice. The offering of the Offered
Securities (including, for greater certainty, any Additional Securities issued in connection with the exercise of the Over-Allotment Option) by the Corporation is hereinafter referred to as the “Offering”. 

 The Offered Securities may be offered to purchasers resident in each of the provinces of Alberta, British
Columbia and Ontario, and such other jurisdictions as the Agent, with the consent of the Corporation, may designate prior to the Closing Date and the Over-Allotment Option Closing Date, as the case may be (the “Public Selling
Jurisdictions”), on a public offering basis. Furthermore, the Offered Securities may be offered to purchasers resident in the United States and such other jurisdictions as the Agent, with the consent of the Corporation, may designate prior
to the Closing Date and the Over-Allotment Option Closing Date, as the case may be (the “Private Selling Jurisdictions”), on a private placement basis. The Public Selling Jurisdictions and the Private Selling Jurisdictions are
collectively referred to as the “Selling Jurisdictions”. The Agent is entitled to appoint a soliciting dealer group consisting of other registered dealers acceptable to the Corporation for the purposes of arranging for purchasers of
the Offered Securities. 
 DEFINITIONS 

In this Agreement, 
 “1933 Act” means the
United States Securities Act of 1933; 
 “1934 Act” means the United States Securities Exchange Act of 1934; 

“Additional Securities” has the meaning ascribed thereto in the third paragraph of this Agreement; 

“Additional Shares” has the meaning ascribed thereto in the third paragraph of this Agreement; 

“Additional Warrants” has the meaning ascribed thereto in the third paragraph of this Agreement; 

“affiliate”, and “associate” shall have the respective meanings ascribed thereto in the Securities Act (British
Columbia); 
 “Agency Fee” has the meaning ascribed thereto in Section 8; 

“Agent” has the meaning ascribed thereto in the first paragraph of this Agreement; 

“Agreement” means this agreement between the Corporation and the Agent dated as of the date hereof; 

“Applicable IP Laws” means all applicable federal, provincial, state and local laws and regulations applicable to Intellectual Property in
Canada, the United States and the jurisdictions in which the Corporation and/or the Subsidiary has registered Intellectual Property or pending Intellectual Property applications; 

“Applicable Laws” means all applicable federal, provincial, state and local laws and regulations of authorities having jurisdiction over the
Corporation, the Subsidiary or the Agent, as applicable; 
 “Applicable Securities Laws” means, collectively, the applicable securities
laws of each of the Selling Jurisdictions and the states thereof, and, in each case, the respective regulations, rules and orders made and forms prescribed thereunder together with all applicable published policy statements, blanket orders and
rulings of the securities regulators in the Selling Jurisdictions; 
 “Broker Shares” means the Common Shares issuable upon exercise of any
Broker Warrants; 
 “Broker Warrant Certificates” means the certificates representing the Broker Warrants, which contains the terms and
conditions of the Broker Warrants; 

  
 - 2 - 

 “Broker Warrants” has the meaning ascribed thereto in Section 8; 

“Business Day” means a day which is not a Saturday, a Sunday or a statutory holiday in the City of Toronto, Ontario or the City of Vancouver,
British Columbia; 
 “CDS” means CDS Clearing and Depository Services Inc., or its nominee; 

“Claims” has the meaning ascribed thereto in Section 13; 

“CIPO” means the Canadian Intellectual Property Office; 

“Clinical Trials” has the meaning ascribed thereto in subsection 6(yyy); 

“Closing” means the closing of the issue and sale by the Corporation of the Offered Securities, including the Additional Securities; 

“Closing Date” means January 9, 2018 or such other date or dates as the Corporation and the Agent may agree upon in writing, it being
acknowledged that the Closing may be completed in one or more tranches as may be determined by the Corporation and the Agent; 
 “Closing
Time” means 8:00 a.m. (Eastern time) on the Closing Date or such other time on the Closing Date as the Corporation and the Agent may agree; 

“Common Shares” means the common shares in the capital of the Corporation; 

“Concurrent Offering” means the concurrent non-brokered private placement of Offered Securities at
the Offering Price to be completed by the Corporation for aggregate gross proceeds of approximately $675,000; 
 “Corporation” has the
meaning ascribed thereto in the first paragraph of this Agreement;  
 “Corporation IP” means the Intellectual Property that has
been developed by or for or is being developed by or for the Corporation and/or the Subsidiary or that is being used by the Corporation and/or the Subsidiary, other than Licensed IP; 

“Corporation’s Auditors” means the firm of accountants appointed by the shareholders of the Corporation and serving as the auditors of
the Corporation at the relevant time; 
 “CPRIT Agreement” means the definitive agreement entered into with the Cancer
Prevention & Research Institute of Texas providing for, among other things, the Corporation being entitled to receive matching funds of up to a maximum of US$12,000,000 on and subject to the terms and conditions therein; 

“Disclosure Record” means all information contained in any press releases, material change reports, financial statements, prospectuses,
annual and quarterly reports or other document of the Corporation which has been publicly filed on SEDAR by, or on behalf of, the Corporation pursuant to Applicable Securities Laws of the Canadian Selling Jurisdictions; 

“Distribution” means “distribution” or “distribution to the public” as those terms are defined under Applicable
Securities Laws of the Canadian Selling Jurisdictions; 
 “Due Diligence Session” has the meaning ascribed thereto in subsection 6(uuu);

  
 - 3 - 

 “Enforceability Qualifications” means (a) bankruptcy, insolvency, reorganization,
moratorium and other laws relating to or affecting the rights of creditors generally, (b) the application of equitable principles when equitable remedies are sought, including the remedies of specific performance and injunctive relief, and
(c) applicable laws limiting rights to indemnity, contribution, waiver, and the ability to sever unenforceable terms; 
 “Environmental
Laws” has the meaning ascribed thereto in subsection 6(ii); 
 “FDA” means the U.S. Food and Drug Administration of the U.S.
Department of Health & Human Services; 
 “Financial Statements” means the audited consolidated financial statements of the
Corporation for the fiscal years ended September 30, 2017, 2016 and 2015; 
 “General Solicitation” and “General
Advertising” means “general solicitation” and “general advertising”, respectively, as used under Rule 502(c) of Regulation D under the U.S. Securities Act, including advertisements, articles, notices or other
communications published in any newspaper, magazine or similar media or broadcast over radio or television or the internet, or any seminar or meeting whose attendees had been invited by general solicitation or general advertising; 

“IFRS” means International Financial Reporting Standards; 

“Indemnified Parties” has the meaning ascribed thereto in Section 13; 

“Intellectual Property” means intellectual property rights, including: (i) all patents, patent rights, inventions, industrial designs
and licenses; (ii) trademarks, service marks, trade dress, trade names, corporate names, logos, slogans and Internet domain names, together with all goodwill associated with each of the foregoing, whether registered or unregistered;
(iii) registered or unregistered copyrights and copyrightable works in whatever form or medium; (iv) registrations, applications and renewals for any of the foregoing; (v) proprietary computer software (including data, data bases and
documentation); and (vi) trade secrets, confidential information and know-how;  

“Lease” means the lease agreement executed on August 25, 2014 by and between Greenpark II Medical LLC and the Subsidiary; 

“Leased Premises” has the meaning ascribed thereto in subsection 6(aa); 

“Licensed IP” means the Intellectual Property owned by any person other than the Corporation and the Subsidiary and which the Corporation
and/or the Subsidiary uses; 
 “Material Adverse Effect” means any change, effect, event, occurrence or change in a state of facts that is,
or would reasonably be expected to be, individually or in the aggregate, material and adverse to the business, operations, financial condition, results, assets, properties, rights, liabilities or prospects of the Corporation and the Subsidiary taken
as a whole; 
 “material change” means a material change for the purposes of Applicable Securities Laws or any of them or where undefined
under Applicable Securities Laws of a jurisdiction means a change in the business, operations or capital of the Corporation that would reasonably be expected to have a significant effect on the market price or value of the Corporation’s
securities and includes a decision to implement such a change made by the Corporation’s board of directors or by senior management of the Corporation who believe that confirmation of the decision by the board of directors is probable; 

  
 - 4 - 

 “material fact” means a material fact for the purposes of Applicable Securities Laws or any of
them or where undefined under Applicable Securities Laws of a jurisdiction means a fact that significantly affects, or would reasonably be expected to have a significant effect on, the market price or value of the Corporation’s securities; 

“Material Permits” has the meaning ascribed thereto in subsection 6(a); 

“misrepresentation” means a misrepresentation for the purposes of Applicable Securities Laws or any of them or where undefined under
Applicable Securities Laws of a jurisdiction means (i) an untrue statement of a material fact, or (ii) an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in the light
of the circumstances in which it was made; 
 “Money Laundering Laws” has the meaning ascribed thereto in subsection 6(aaaa); 

“NASDAQ” means the Nasdaq Capital Market; 

“NI 45-106” means National Instrument 45-106 –
Prospectus Exemptions; 
 “NI 51-102” means National Instrument 51-102 – Continuous Disclosure Obligations; 
 “Notice” has the meaning ascribed thereto in
Section 23; 
 “Offered Securities” means, collectively, the Offered Shares and the Warrants; 

“Offered Shares” has the meaning ascribed thereto in the second paragraph of this Agreement; 

“Offering” has the meaning ascribed thereto in the third paragraph of this Agreement; 

“Offering Price” has the meaning ascribed thereto in the second paragraph of this Agreement; 

“Original A&R Agreement” has the meaning ascribed thereto in the first paragraph of this Agreement; 

“Over-Allotment Option” has the meaning ascribed thereto in the third paragraph of this Agreement; 

“Over-Allotment Option Closing Date” has the meaning ascribed thereto in the third paragraph of this Agreement; 

“Over-Allotment Option Closing Time” means 8:00 a.m. (Vancouver time) on the Over-Allotment Option Closing Date or such other time on the
Over-Allotment Option Closing Date as the Corporation and the Agent may agree; 
 “Partially Excluded Purchasers” means the persons set
forth in Schedule “C” of this Agreement; 
 “Prospectus” means, collectively, the prospectus supplement dated the date hereof and
any amendments thereto and the base shelf prospectus dated December 22, 2015, together with all documents incorporated by reference therein; 

“Private Selling Jurisdictions” has the meaning ascribed thereto in the fourth paragraph of this Agreement; 

“Public Selling Jurisdictions” has the meaning ascribed thereto in the fourth paragraph of this Agreement; 

  
 - 5 - 

 “Registered Corporation IP” means all Corporation IP that is the subject of registration or
pending application for registration with a national intellectual property office (including the CIPO and the USPTO); 
 “Regulation S”
means Regulation S adopted under the 1933 Act; 
 “Regulatory Authority” means the statutory or governmental bodies authorized under
applicable laws to protect and promote public health through regulation and supervision of therapeutic drug candidates intended for use in humans, including the FDA and Health Canada; 

“Rule 144” has the meaning ascribed thereto in subsection 7(h); 

“SEC” means the United States Securities and Exchange Commission; 

“Securities” means and includes, individually and collectively, the Offered Shares, the Warrants, the Warrant Shares, the Broker Warrants and
the Broker Shares; 
 “Securities Commissions” means the securities commissions or similar regulatory authorities in the Selling
Jurisdictions; 
 “SEDAR” means the system for electronic document analysis and retrieval operated by the Canadian Securities
Administrators; 
 “Selling Jurisdictions” has the meaning ascribed thereto in the fourth paragraph of this Agreement; 

“Shares” means, collectively, the Offered Shares, the Warrant Shares and the Broker Shares; 

“Subsidiary” means ESSA Pharmaceuticals Corp.; 

“Taxes” has the meaning ascribed thereto in subsection 6(n); 

“to the best of the Corporation’s knowledge” or “to the Corporation’s knowledge” or “known to the
Corporation” or similar language describing facts known to the Corporation or its agents and associates, means matters relating to the Corporation that are known, after due inquiry, to any of the Corporation’s current president,
principal executive officer or principal financial officer; 
 “Transaction Documents” has the meaning ascribed thereto in subsection 6(a);

 “Transfer Agent” means Computershare Investor Services Inc. as registrar and transfer agent for the Common Shares and the preferred
shares in the capital of the Corporation; 
 “TSXV” means the TSX Venture Exchange; 

“U.S. Agent” has the meaning ascribed thereto in Section 2; 

“U.S. Investors” means any person in the United States or any U.S. Person who purchases Offered Securities in the Offering; 

“U.S. Person” has the meaning defined in Regulation S under the 1933 Act; 

“U.S. Resale Registration” has the meaning ascribed thereto in Section 4; 

  
 - 6 - 

 “United States” means the United States of America, its territories and possessions, any state
of the United States, and the District of Columbia; 
 “USPTO” means the United States Patent and Trademark Office; 

“Voting Agreement” means the voting agreement dated January 14, 2016 between Clarus Lifesciences III, L.P. and certain shareholders of
the Corporation; 
 “Warrant” has the meaning ascribed thereto in the second paragraph of this Agreement; 

“Warrant Certificates” means the certificates representing the Warrants, which contains the terms and conditions of the Warrants; and 

“Warrant Share” has the meaning ascribed thereto in the second paragraph of this Agreement. 

Unless otherwise expressly provided in this Agreement, words importing only the singular number include the plural and vice versa and words importing gender
include all genders. References to “Sections”, “subsections” or “clauses” are to the appropriate section, subsection or clause of this Agreement. References to any agreement or instrument, including this Agreement, are
deemed to be references to the agreement or instrument as varied, amended, modified, supplemented or replaced from time to time, references herein to “including” shall mean “including, without limitation”, and any specific
references herein to any legislation or enactment are deemed to be references to such legislation or enactment as the same may be amended or replaced from time to time. 

The following are the schedules attached to this Agreement, which schedules are deemed to be a part hereof and are hereby incorporated by reference herein:

  

					
	Schedule “A”	 	-	    	Terms and Conditions for United States Offers and Sales
			
	Schedule “B”	 	-	    	Convertible Securities
			
	Schedule “C”	 	-	    	Partially Excluded Purchasers
			
	Schedule “D”	 	-	    	Registered Corporation IP

 TERMS AND CONDITIONS 
  

	1.	Appointment of Agent 

 Based upon the foregoing and subject to the terms and conditions set out below,
the Corporation hereby appoints the Agent and the Agent hereby accepts such appointment, to effect the sale of the Offered Securities at the Offering Price, on a best efforts basis to persons resident in the Selling Jurisdictions. The Agent agrees
to use its best efforts to sell the Offered Securities, but it is hereby understood and agreed that the Agent shall act as agent only and is under no obligation to purchase any of the Offered Securities, although the Agent may subscribe for Offered
Securities, subject to Applicable Laws. The Agent shall be entitled to appoint a soliciting dealer group consisting of other registered dealers acceptable to the Corporation for the purpose of arranging for purchases of the Offered Securities. 

 

	2.	U.S. Sales 

 The parties acknowledge that the Securities have not been registered under the 1933 Act and
may not be offered or sold in the United States or to, or for the account or benefit of, U.S. Persons except pursuant to exemptions from the registration requirements of the 1933 Act and the applicable laws of any applicable state of the United
States. Accordingly, the Corporation and the Agent agree that any offers or sales of the Offered Securities in the United States or to, or for the account or benefit of, U.S. Persons shall be conducted only in the manner specified in Schedule
“A” hereof. All actions to be undertaken by the Agent in the United States in connection with the matters contemplated herein shall be undertaken through H.C. Wainwright & Co., LLC, a duly registered broker-dealer in the United
States engaged in connection with such offer or sale (the “U.S. Agent”). 

  
 - 7 - 

	3.	Prospectus 

 The Corporation shall use commercially reasonable best efforts to file the Prospectus in
each of the Canadian Selling Jurisdictions not later than 10:45 p.m. (Toronto time) on January 5, 2018. 
 Until the date on which the Distribution of
the Offered Securities is completed, the Corporation will promptly take, or cause to be taken, all additional steps and proceedings that may from time to time be required or desirable under Applicable Securities Laws of the Canadian Selling
Jurisdictions to continue to qualify the Distribution of the Offered Securities and the Broker Warrants, or, in the event that the Offered Securities and the Broker Warrants have, for any reason, ceased to so qualify, to so qualify again the Offered
Securities and the Broker Warrants for Distribution in the Canadian Selling Jurisdictions. 
  

	4.	U.S. Resale Registration 

 The Company shall use its reasonable best efforts to: (i) file a U.S.
registration statement, or a prospectus supplement to its existing U.S. shelf registration statement on Form F-10, with the SEC relating to resales, from time to time, by the U.S. Investors in this Offering of
the Offered Shares and the Warrant Shares held by such U.S. Investors (the “U.S. Resale Registration”) as soon as practicable after the initial Closing Date and the Over-Allotment Option Closing Date, as the case may be, but in no
event more than 10 Business Days after the initial Closing Date and the Over-Allotment Option Closing Date, as the case may be; (ii) have the U.S. Resale Registration become, or be declared effective by the SEC, no later than: (x) 30 calendar
days (if the SEC does not review the U.S. Resale Registration); or (y) 75 calendar days (if the SEC does review the U.S. Resale Registration), in each case, from the applicable filing date; and (iii) maintain the effectiveness of such U.S.
Resale Registration until such time as all of the Offered Shares or Warrant Shares may be resold by such U.S. Investors without restriction pursuant to Rule 144. 
  

	5.	Certain Representations, Warranties, Covenants and Obligations of the Agent 

  

	(1)	The Agent hereby covenants to the Corporation as follows: 

  

	 	(a)	the Agent has complied and will comply with Applicable Securities Laws in connection with the Distribution of the Offered Securities upon the terms and conditions set out in the Prospectus and this Agreement. The Agent
has offered and will offer, for sale to the public and sell the Offered Securities only in those jurisdictions where they may be lawfully offered for sale or sold; 

 

	 	(b)	the Agent shall distribute the Offered Securities in a manner which complies with and observes all Applicable Laws in each jurisdiction into and from which it may offer to sell Offered Securities or distribute the
Prospectus in connection with the Distribution of the Offered Securities; 

  

	 	(c)	for the purposes of this Section 5, the Agent shall be entitled to assume that the Offered Securities and the Broker Warrants are qualified for Distribution in each of the provinces of British Columbia, Alberta and
Ontario; 

  
 - 8 - 

	 	(d)	the Agent shall deliver a copy of the Prospectus to each investor; 

  

	 	(e)	any offers and sales of Offered Securities and the other Securities in the United States or to, or for the account or benefit of, U.S. Persons shall be made in accordance with the terms and conditions set out in
Schedule “A” to this Agreement, which schedule is incorporated by reference and forms part of this Agreement. The Corporation and the Agent shall, and the Agent shall cause the U.S. Agent to, comply with the terms and conditions set out
therein. The Agent shall cause the representations, warranties and covenants included in Schedule “A” hereto to be made by the U.S. Agent for the benefit of the Corporation; 

 

	 	(f)	it will not engage in any form of General Solicitation or General Advertising in connection with the offer and sale of the Offered Securities; 

 

	 	(g)	it will not solicit subscriptions for Offered Securities or other Securities except in accordance with the terms and conditions of this Agreement; 

 

	 	(h)	it will not, in connection with the Offering, make any representation or warranty with respect to the Offered Securities, the other Securities or the Corporation other than as set forth in this Agreement or the
Prospectus; and 

  

	 	(i)	it will provide to the Corporation all necessary information in respect of the Agent and the investors (and will use its commercially reasonable efforts to provide to the Corporation all necessary information in respect
of the U.S. Agent) to allow the Corporation to file, with the Securities Commissions, if required, reports of the sale of the Offered Securities and the other Securities in accordance with Applicable Securities Laws within ten days of the Closing.

  

	(2)	The Agent represents and warrants to the Corporation, and acknowledges that the Corporation is relying upon such representations and warranties in connection with the purchase and sale of the Offered Securities, that:

  

	 	(a)	it is a valid and subsisting corporation, duly incorporated and in good standing under the laws of the jurisdiction in which it was incorporated; 

 

	 	(b)	it holds all licenses and permits that are required for carrying on its business in the manner in which such business has been carried on; 

 

	 	(c)	it has good and sufficient right and authority to enter into this Agreement and complete the transactions contemplated under this Agreement on the terms and conditions set forth herein; 

 

	 	(d)	all information reasonably requested by the Agent and its counsel in connection with the due diligence investigations of the Agent will be treated by the Agent and its counsel as confidential and will only be used in
connection with the Offering; 

  

	 	(e)	it is duly qualified in accordance with Applicable Securities Laws to solicit and procure subscriptions for the Offered Securities in the Selling Jurisdictions in which it is qualified to do so in connection with the
Offering; 

  
 - 9 - 

	 	(f)	it is an “accredited investor” as such term is defined under NI 45-106 by virtue of being a person registered under Applicable Securities Laws and is acquiring the
Broker Warrants as principal for its own account and not for the benefit of any other person; 

  

	 	(g)	it is not a person in the United States or a U.S. Person, the Offered Securities were not offered to it by the Corporation in the United States and it did not sign this Agreement in the United States; and

  

	 	(h)	the U.S. Agent is an institutional “accredited investor” as defined in Rule 501(a)(1), (2), (3) or (7) under the 1933 Act and is acquiring the Broker Warrants for its own account and not for the benefit
of any other person. 

 The Corporation understands and agrees that the Agent may arrange for investors of the Offered Securities in
jurisdictions other than Canada and the United States, on a private placement basis and provided that the purchase of such Offered Securities does not contravene the Applicable Securities Laws of the jurisdiction where the purchaser is resident and
provided that such sale does not trigger: (i) any obligation to prepare and file a prospectus, registration statement or similar disclosure document; or (ii) any registration or other obligation on the part of the Corporation including any
continuing obligation in that jurisdiction. 
  

	6.	Representations and Warranties of the Corporation 

 The Corporation represents and
warrants to the Agent, and acknowledges that the Agent is relying upon such representations and warranties in connection with its execution and delivery of this Agreement and the completion of the Offering, as of the Closing Date and the
Over-Allotment Option Closing Date, as the case may be, as follows: 
  

	 	(a)	the Corporation is a corporation duly organized and validly existing under the laws of the jurisdiction in which it was incorporated, has all requisite corporate power and authority and is duly qualified and holds all
necessary material permits, licences and authorizations (collectively, the “Material Permits”) necessary or required to carry on its business as now conducted and to own, lease or operate its properties and assets and no steps or
proceedings have been taken by any person, voluntary or otherwise, requiring or authorizing its dissolution or winding up, and the Corporation has all requisite power and authority to enter into each of this Agreement, the Warrant Certificates and
the Broker Warrant Certificates, (collectively, the “Transaction Documents”) and to carry out its obligations hereunder and thereunder; 

  

	 	(b)	all such Material Permits which are so required are valid and subsisting and in good standing and none of the same contains any term, provision, condition or limitation which has or would reasonably be expected to
affect or restrict in a materially adverse manner the operation of the business of the Corporation, as now carried on or proposed to be carried on, as set out in the Prospectus, and the Corporation is not in breach thereof or in default with respect
to filings to be effected or conditions to be fulfilled in order to maintain such Material Permits in good standing; 

  

	 	(c)	the Corporation is and at all times has been in material compliance with each Material Permit held by it and is not in violation of, or in default under, any such Material Permit in any material respect, except in any
case where the Corporation has received a valid and effective waiver of such violation or default; 

  
 - 10 - 

	 	(d)	each of the execution and delivery of the Transaction Documents, the performance by the Corporation of its obligations hereunder and thereunder, the issue and sale of the Offered Securities, the performance by the
Corporation of its obligations thereunder and the consummation of the transactions contemplated by the Transaction Documents, do not and will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a
material default under (whether after notice or lapse of time or both) (A) any statute, rule or regulation applicable to the Corporation or the Subsidiary including Applicable Securities Laws or the rules and regulations of the TSXV or NASDAQ;
(B) the constating documents, by-laws or resolutions of the Corporation or the Subsidiary which are in effect at the date hereof; (C) any mortgage, note, indenture, contract, agreement, joint
venture, partnership, instrument, lease or other document to which the Corporation or the Subsidiary is a party or by which the Corporation or the Subsidiary is bound; or (D) any judgment, decree or order binding the Corporation or the
Subsidiary or any of their respective properties or assets; 

  

	 	(e)	other than the Voting Agreement, no agreement is in force or effect which in any manner affects the voting or control of any of the securities of the Corporation to which the Corporation is a party or of which the
Corporation is aware; 

  

	 	(f)	the Corporation does not beneficially own or exercise control or direction over 10% or more of the outstanding voting shares of any company other than the Subsidiary, which is wholly-owned by the Corporation, and all of
the issued and outstanding shares of the Subsidiary are issued as fully paid and non-assessable shares, free and clear of all mortgages, liens, charges, pledges, security interests, encumbrances, claims or
demands whatsoever and no person, firm or corporation has any agreement, option, right or privilege (whether present or future, contingent or absolute, pre-emptive or contractual) capable of becoming an
agreement, for the purchase from the Corporation or the Subsidiary of any interest in any of the shares of the Subsidiary or for the issue or allotment of any unissued shares in the capital of the Subsidiary or any other security convertible into or
exchangeable for any such shares of the Subsidiary; 

  

	 	(g)	the Subsidiary is a corporation duly organized and validly existing under the laws of the jurisdiction in which it was incorporated, has all requisite corporate power and authority and is duly qualified and holds all
necessary material permits, licences and authorizations necessary or required to carry on its business as now conducted and to own, lease or operate its properties and assets and no steps or proceedings have been taken by any person, voluntary or
otherwise, requiring or authorizing its dissolution or winding up; 

  

	 	(h)	the Subsidiary has no material assets or liabilities, is not party to any material agreement and no material revenues are booked through the Subsidiary; 

 

	 	(i)	neither the Corporation nor the Subsidiary is in default or in breach in any material respect of the constating documents, by-laws or resolutions of its directors or shareholders
or any mortgage, note, indenture, contract, agreement, joint venture, partnership, instrument, lease or other document to which the Corporation or the Subsidiary is a party or by which the Corporation or the Subsidiary is bound; 

 

	 	(j)	all consents, approvals, permits, authorizations or filings as may be required under Applicable Securities Laws necessary for (i) the execution and delivery of the Transaction Documents, (ii) the issuance of
the Securities, and (iii) the completion of the transactions contemplated hereby, have been made or obtained, as applicable; 

  
 - 11 - 

	 	(k)	the currently issued and outstanding Common Shares are listed and posted for trading on the TSXV and on the NASDAQ and no order ceasing or suspending trading in the Common Shares or prohibiting the trading of any of the
Common Shares has been issued and no proceedings for such purpose are pending or, to the knowledge of the Corporation, threatened other than: (i) the letter of the NASDAQ dated July 19, 2017 with respect to the Company’s failure to
maintain a minimum US$1.00 closing bid price of US$1.00 per share as required by NASDAQ listing rule 5550(a)(2); and (ii) the letter of the NASDAQ dated July 20, 2017 with respect to the Corporation’s failure to maintain a minimum
market value of listed securities of US$35 million as required by NASDAQ listing rule 5550(b)(2), in each case, as disclosed in the Prospectus; 

  

	 	(l)	neither the Corporation nor the Subsidiary has approved, is contemplating, or has entered into any agreement in respect of, and neither the Corporation nor the Subsidiary has any knowledge of: (A) the purchase of
any property material to the Corporation or the Subsidiary or assets or any interest therein or the sale, transfer or other disposition of any property material to the Corporation or the Subsidiary or assets or any interest therein currently owned,
directly or indirectly, by the Corporation or the Subsidiary whether by asset sale, transfer or sale of shares or otherwise; or (B) the change of control (by sale or transfer of shares or sale of all or substantially all of the property and
assets of the Corporation or the Subsidiary) of the Corporation or the Subsidiary; 

  

	 	(m)	the Financial Statements have been prepared in accordance with IFRS accepted in Canada and consistently applied throughout the period referred to therein, contain no misrepresentation and present fully, fairly and
correctly, in all material respects, the financial condition of the Corporation and the Subsidiary as at the dates thereof and the results of the operations and the changes in the financial position of the Corporation and the Subsidiary for the
periods then ended and contain and reflect adequate provisions or allowance for all reasonably anticipated liabilities, expenses and losses of the Corporation and the Subsidiary and there has been no change in accounting policies or practices of the
Corporation and the Subsidiary since September 30, 2017, other than as required by IFRS or as disclosed in the Financial Statements; 

  

	 	(n)	all taxes (including income tax, capital tax, payroll taxes, employer health tax, workers’ compensation payments, property taxes, custom and land transfer taxes), duties, royalties, levies, imposts, assessments,
deductions, charges or withholdings and all liabilities with respect thereto including any penalty and interest payable with respect thereto (collectively, “Taxes”) due and payable by the Corporation and the Subsidiary have been
paid, except where the failure to pay such taxes would not have a Material Adverse Effect. All tax returns, declarations, remittances and filings required to be filed by each of the Corporation and the Subsidiary have been filed with all appropriate
governmental authorities and all such returns, declarations, remittances and filings are complete and accurate and no material fact or facts have been omitted therefrom which would make any of them misleading, except where such failure would not
have a Material Adverse Effect. To the best of the Corporation’s knowledge, no examination of any tax return of the Corporation of the Subsidiary is currently in progress and there are no issues or disputes outstanding with any governmental
authority respecting any Taxes that have been paid, or may be payable, by the Corporation or the Subsidiary, in any case, except where such examinations, issues or disputes would not constitute an adverse material fact in respect of the Corporation
or the Subsidiary or have a Material Adverse Effect; 

  
 - 12 - 

	 	(o)	other than in respect of the Concurrent Offering, no holder of outstanding shares in the capital of the Corporation will be entitled to any pre-emptive or any similar rights to
subscribe for any Common Shares or other securities of the Corporation and, other than as set out in Schedule “B” attached hereto, no rights, warrants or options to acquire, or instruments convertible into or exercisable or exchangeable
for, any shares in the capital of the Corporation or the Subsidiary are outstanding; 

  

	 	(p)	all documents in the Disclosure Record contain no misrepresentation as of the date of the statements in the Disclosure Record and were prepared in accordance with and comply with Applicable Securities Laws of the
Canadian Selling Jurisdictions; 

  

	 	(q)	no legal or governmental proceedings or inquiries are pending to which the Corporation or the Subsidiary is a party or to which their respective properties are subject that would result in the revocation or modification
of any material contract, order, certificate, right, authority, permit or license necessary to conduct the business now owned or operated by the Corporation or the Subsidiary which, if the subject of an unfavourable decision, ruling or finding would
have a Material Adverse Effect and, to the knowledge of the Corporation, no such legal or governmental proceedings or inquiries have been threatened against or are contemplated with respect to the Corporation or the Subsidiary or with respect to
their respective properties; 

  

	 	(r)	the Corporation is the legal and beneficial owner, free of all mortgages, liens, charges, pledges, security interests, encumbrances, claims or demands whatsoever, of the interests in personal property referred to as
owned by it in the Prospectus, and all material agreements under which the Corporation holds an interest in personal property are in good standing according to their terms; 

 

	 	(s)	neither the Corporation nor the Subsidiary is in default in the performance or observance of any material obligation, agreement, covenant or condition contained in any contract, indenture, trust deed, mortgage, loan
agreement, note, lease or other agreement or instrument to which it is a party or by which it or its property may be bound; 

  

	 	(t)	the Corporation or the Subsidiary, as applicable, owns or has the right to use under license, sub-license or otherwise all Intellectual Property used by the Corporation or the
Subsidiary; 

  

	 	(u)	any and all of the agreements and other documents and instruments pursuant to which the Corporation or the Subsidiary holds the property and assets thereof (including any interest in, or right to earn an interest in,
any property) are valid and subsisting agreements, documents or instruments in full force and effect, enforceable in accordance with terms thereof. Neither the Corporation nor the Subsidiary is in default of any of the material provisions of any
such agreements, documents or instruments nor has any such default been alleged and such properties and assets are in good standing under the applicable statutes and regulations of the jurisdictions in which they are situated, all leases, licences
and claims pursuant to which the Corporation or the Subsidiary derive the interests thereof in such property and assets are in good standing and there has been no material default under any such lease, licence or claim. The properties (or any
interest in, or right to earn an interest in, any property) of each of the Corporation and the Subsidiary are not subject to any right of first refusal or purchase or acquisition right; 

  
 - 13 - 

	 	(v)	the Transaction Documents have been or will be, as of the Closing Time, duly authorized and executed and delivered by the Corporation and constitute or will constitute valid and binding obligations of the Corporation
enforceable against the Corporation in accordance with their respective terms, except as enforcement thereof may be limited by the Enforceability Qualifications; 

  

	 	(w)	at the Closing Time all necessary corporate action will have been taken by the Corporation to: (i) validly issue the Offered Shares as fully paid and non-assessable
securities of the Corporation; (ii) validly create and issue the Warrants and Broker Warrants; and (iii) allot and reserve the Warrant Shares and Broker Shares, which upon issuance in accordance with the terms of such securities shall be
validly issued as fully paid and non-assessable securities in the capital of the Corporation; 

  

	 	(x)	the authorized capital of the Corporation consists of an unlimited amount of Common Shares and an unlimited amount of preferred shares of which, as at the close of business on the Business Day immediately preceding the
date hereof, 29,101,889 Common Shares and nil preferred shares were issued and outstanding as fully paid and non-assessable shares in the capital of the Corporation. There is sufficient authorized capital for
the issuance of all Common Shares issuable on exercise of all Securities and all outstanding convertible securities of the Corporation; 

  

	 	(y)	the Prospectus contains all material facts with respect to the Corporation, the Subsidiary, its material contracts and the Corporation’s business and does not contain a misrepresentation; provided, however, that
this representation and warranty shall not apply to any statements made in reliance upon and conformity with information and statements relating solely to the Agent which has been provided by the Agent to the Corporation in writing specifically for
use in the Prospectus; 

  

	 	(z)	except for the Corporation guaranteeing certain obligations of the Subsidiary under the Lease, neither the Corporation nor the Subsidiary has made any loans to or guaranteed the obligations of any person;

  

	 	(aa)	with respect to each premises of the Corporation and the Subsidiary which is material to each of the Corporation and the Subsidiary and which each of the Corporation and the Subsidiary occupies as tenant (each, a
“Leased Premises”), each of the Corporation and the Subsidiary occupies its respective Leased Premises and has the exclusive right to occupy and use such Leased Premises and each of the leases pursuant to which the Corporation and
the Subsidiary occupies its respective Leased Premises is in good standing and in full force and effect; 

  

	 	(bb)	the Corporation does not have any loans or other indebtedness outstanding which have been made to any of its officers, directors or employees, past or present, any known holder of more than 10% of any class of shares of
the Corporation, or any person not dealing at arm’s length with the Corporation that are currently outstanding; 

  

	 	(cc)	except as disclosed herein and in the Disclosure Record, none of the directors, officers or employees of the Corporation, any known holder of more than 10% of any class of shares of the Corporation, or any associate or
affiliate of any of the foregoing persons, had or has any material interest, direct or indirect, in any transaction or any proposed transaction that was or is material to the Corporation; 

  
 - 14 - 

	 	(dd)	each of the Corporation and the Subsidiary is in compliance with all Applicable Laws respecting employment and employment practices, terms and conditions of employment, pay equity and wages, except where non-compliance with such laws could not reasonably be expected to have a Material Adverse Effect, and neither the Corporation nor the Subsidiary has or is engaged in any unfair labour practice; 

 

	 	(ee)	none of the directors, officers or employees of the Corporation or the Subsidiary or any associate or affiliate of any of the foregoing had or has any material interest, direct or indirect, in any transaction or any
proposed transaction with the Corporation or the Subsidiary which, as the case may be, materially affects, is material to or will materially affect the Corporation or the Subsidiary; 

 

	 	(ff)	there have not been and there are not currently any material disagreements with any employee or employees of the Corporation or the Subsidiary which are adversely affecting or could adversely affect the business of the
Corporation or the Subsidiary; 

  

	 	(gg)	the assets of each of the Corporation and the Subsidiary and their respective businesses and operations are insured against loss or damage with responsible insurers on a basis consistent with insurance obtained by
reasonably prudent participants in comparable businesses, and such coverage is in full force and effect, and neither the Corporation nor the Subsidiary has failed to promptly give any notice of any material claim thereunder; 

 

	 	(hh)	the minute books and records of each of the Corporation and the Subsidiary made available to counsel for the Agent in connection with its due diligence investigation of the Corporation and the Subsidiary for the periods
from each of the Corporation’s and the Subsidiary’s date of incorporation to the date hereof are all of the minute books and records of the Corporation and the Subsidiary, respectively, and contain copies of all proceedings (or certified
copies thereof or drafts thereof pending approval) of the shareholders, the directors and all committees of directors of the Corporation and the Subsidiary to the date of review of such corporate records and minute books and there have been no other
meetings, resolutions or proceedings of the shareholders, directors or any committees of the directors of the Corporation or the Subsidiary to the date hereof not reflected in such minute books and other records, other than the resolutions approving
the Offering and the Concurrent Offering; 

  

	 	(ii)	in connection with the ownership, use, maintenance or operation of their properties and assets, including the Leased Premises, neither the Corporation nor the Subsidiary has been in violation of any applicable federal,
provincial, municipal or local laws, by-laws, regulations, orders, policies, permits, licences, certificates or approvals having the force of law, domestic or foreign, relating to environmental, health or
safety matters (collectively the “Environmental Laws”) which violation would have a Material Adverse Effect; 

  
 - 15 - 

	 	(jj)	without limiting the generality of subsection 6(ii), the Corporation does not have any knowledge of, and has not received any notice of, any material claim, judicial or administrative proceeding, pending or threatened
against, or which may affect the Corporation or the Subsidiary or any of the property, assets or operations thereof, relating to, or alleging any violation of any Environmental Laws; to the Corporation’s knowledge, there are no facts which
could give rise to any such claim or judicial or administrative proceeding; to the best of the Corporation’s knowledge, neither the Corporation nor the Subsidiary nor any of the property, assets or operations thereof is the subject of any
investigation, evaluation, audit or review by any Governmental Authority (which term means and includes any national, federal government, province, state, municipality or other political subdivision of any of the foregoing, any entity exercising
executive, legislative, judicial, regulatory or administrative functions of or pertaining to government and any corporation or other entity owned or controlled (through stock or capital ownership or otherwise) by any of the foregoing) to determine
whether any violation of any Environmental Laws has occurred or is occurring or whether any remedial action is needed in connection with a release of any contaminant into the environment, except for compliance investigations conducted in the normal
course by any governmental authority, in each case which could reasonably be expected to have a Material Adverse Effect; 

  

	 	(kk)	no order, ruling or determination having the effect of suspending the sale or ceasing the trading in any securities of the Corporation has been issued by any securities regulatory authority and is continuing in effect
and no proceedings for that purpose have been instituted or, to the knowledge of the Corporation, are pending, contemplated or threatened by any securities regulatory authority; 

 

	 	(ll)	there are no orders, rulings or directives issued, pending or, to the best of the Corporation’s knowledge, threatened against the Corporation or the Subsidiary under or pursuant to any Environmental Laws requiring
any work, repairs, construction or capital expenditures with respect to the property or assets of the Corporation or the Subsidiary (including the Leased Premises) which would have a Material Adverse Effect; 

 

	 	(mm)	other than the Agent and the U.S. Agent, there is no person acting or purporting to act at the request or on behalf of the Corporation that is entitled to any brokerage or finder’s fee in connection with the
transactions contemplated by this Agreement; 

  

	 	(nn)	the Transfer Agent has been duly appointed as registrar and transfer agent for the Common Shares and preferred shares of the Corporation; 

 

	 	(oo)	except pursuant to the CPRIT Agreement, the Corporation and the Subsidiary are the sole legal and beneficial owners of, have good and marketable title to, and own all right, title and interest in all Corporation IP free
and clear of all encumbrances, charges, covenants, conditions, options to purchase and restrictions or other adverse claims or interest of any kind or nature, and the Corporation has no knowledge of any claim of adverse ownership in respect thereof.
Schedule “D” to this Agreement contains a true and complete list of all active (including reinstatable) Registered Corporation IP. No consent of any person is necessary to make, use, reproduce, license, sell, modify, update, enhance or
otherwise exploit any Corporation IP and none of the Corporation IP comprises an improvement to Licensed IP that would give any person any rights to the Corporation IP, including rights to license the Corporation IP. Each of the Corporation and the
Subsidiary has a valid and enforceable right to the Licensed IP used or held for use in the business of each of the Corporation and the Subsidiary; 

  

	 	(pp)	neither the Corporation nor the Subsidiary has received any notice or claim (whether written, oral or otherwise) challenging in any manner whatsoever either the Corporation’s or the Subsidiary’s ownership or
right to use any of the Corporation IP or suggesting that any other person has any claim of legal or beneficial ownership or other claim or interest with respect thereto, nor, to the knowledge of the Corporation (including its officers, directors
and employees, and the Corporation’s Intellectual Property consultants and managers including Kally Singh), is there a reasonable basis for any claim that any person other than the Corporation or the Subsidiary has any claim of legal or
beneficial ownership or other claim or interest in any of the Corporation IP; 

  
 - 16 - 

	 	(qq)	all applications for registration of any Registered Corporation IP are in good standing, are recorded in the name of the Corporation or the Subsidiary and have been filed in a timely manner in the appropriate offices to
preserve the rights thereto and, in the case of a provisional application, the Corporation confirms that all right, title and interest in and to the invention(s) disclosed in such application have been or as of the initial Closing Date and the
Over-Allotment Option Closing Date, as the case may be, will be assigned in writing (without any express right to revoke such assignment) to the Corporation or the Subsidiary. There has been no public disclosure, sale or offer for sale of any
Corporation IP by the Corporation anywhere in the world that may prevent the valid issue of all available Intellectual Property rights in such Corporation IP. All material prior art or other information has been disclosed to the appropriate offices
as required in accordance with Applicable IP Laws in the jurisdictions where the applications are pending; 

  

	 	(rr)	all registrations of Registered Corporation IP are in good standing and are recorded in the name of the Corporation or the Subsidiary in the appropriate offices to preserve the rights thereto. All such registrations
have been filed, prosecuted and obtained in accordance with all Applicable IP Laws and are currently in effect and in compliance with all Applicable IP Laws. To the knowledge of the Corporation (including its officers, directors and employees, and
the Corporation’s Intellectual Property consultants and managers including Kally Singh), no registration of Registered Corporation IP has expired, become abandoned, been cancelled or expunged, or has lapsed for failure to be renewed, maintained
or otherwise; 

  

	 	(ss)	the conduct of the business of each of the Corporation and the Subsidiary (including the use or other exploitation of the Corporation IP by each of the Corporation and the Subsidiary or other licensees) has not
infringed, violated, misappropriated or otherwise conflicted with, and, to the knowledge of the Corporation (including its officers, directors and employees, and the Corporation’s Intellectual Property consultants and managers including Kally
Singh), does not infringe, violate, misappropriate or otherwise conflict with any Intellectual Property right of any person; 

  

	 	(tt)	neither the Corporation nor the Subsidiary is a party to any action or proceeding, nor, to the knowledge of the Corporation (including its officers, directors and employees, and the Corporation’s Intellectual
Property consultants and managers including Kally Singh), is or has any action or proceeding been threatened that alleges that any current or proposed conduct of the business of each of the Corporation and the Subsidiary (including the use or other
exploitation of any Corporation IP by the Corporation or the Subsidiary or any customers, distributors or other licensees) has or will infringe, violate or misappropriate or otherwise conflict with any Intellectual Property right of any person;

  

	 	(uu)	to the knowledge of the Corporation (including its officers, directors and employees, and the Corporation’s Intellectual Property consultants and managers including Kally Singh), no person has interfered with,
infringed upon, misappropriated, illegally exported, or violated any rights with respect to the Corporation IP; 

  
 - 17 - 

	 	(vv)	the Corporation has entered into valid and enforceable written agreements pursuant to which the Corporation has been granted all licenses and permissions to use, reproduce, sub license, sell, modify, update, enhance or
otherwise exploit the Licensed IP to the extent required to operate all aspects of the business of the Corporation currently conducted (including, if required, the right to incorporate such Licensed IP into the Corporation IP). All license
agreements in respect of the Licensed IP are in full force and effect, and neither the Corporation nor, to the knowledge of the Corporation (including its officers, directors and employees, and the Corporation’s Intellectual Property
consultants and managers including Kally Singh), any other person is in default of its obligations thereunder; 

  

	 	(ww)	to the extent that any of the Corporation IP is licensed or disclosed to any person or any person has access to such Corporation IP (including any employee, officer, shareholder or consultant of the Corporation or the
Subsidiary), each of the Corporation and the Subsidiary has entered into a valid and enforceable written agreement which contains terms and conditions prohibiting the unauthorized use, reproduction, disclosure, reverse engineering or transfer of
such Corporation IP by such person. All such agreements are in full force and effect, and neither the Corporation nor the Subsidiary nor, to the knowledge of the Corporation (including its officers, directors and employees, and the
Corporation’s Intellectual Property consultants and managers including Kally Singh), any other person is in default of its obligations thereunder; 

  

	 	(xx)	each of the Corporation and the Subsidiary has taken all actions that are contractually obligated to be taken and all actions that are customary and reasonable to protect the confidentiality of the Corporation IP;

  

	 	(yy)	it is not, and will not be, necessary for the Corporation or the Subsidiary to utilize any Intellectual Property owned by or in possession of any of the employees (or people the Corporation or the Subsidiary currently
intends to hire) made prior to their employment with the Corporation or the Subsidiary in violation of the rights of such employee or any of his or her prior employers; 

 

	 	(zz)	neither the Corporation nor the Subsidiary has received any advice or any opinion that any of the Corporation IP is invalid or unregistrable or unenforceable, in whole or in part; 

 

	 	(aaa)	neither the Corporation nor the Subsidiary has received any grant relating to research and development which is subject to repayment in whole or in part or to conversion to debt upon sale of any securities of the
Corporation or the Subsidiary or which may affect the right of ownership of the Corporation or the Subsidiary in the Corporation IP; 

  

	 	(bbb)	each of the Corporation and the Subsidiary has and enforces a policy requiring each employee and consultant to execute a non-disclosure agreement substantially in the forms
provided to the Agent and Agent’s counsel, and all current employees and consultants of each of the Corporation and the Subsidiary have executed such agreement and, to the knowledge of the Corporation (including its officers, directors and
employees, and the Corporation’s Intellectual Property consultants and managers including Kally Singh), all past employees and consultants of each of the Corporation and the Subsidiary have executed such agreement; 

 

	 	(ccc)	all of the present and past employees of the Corporation and the Subsidiary, and all of the present and past consultants, contractors and agents of the Corporation and the Subsidiary performing services relating to the
development, modification or support of the Corporation IP, have entered into a written agreement assigning to the Corporation and the Subsidiary, as applicable, all right, title and interest in and to all such Intellectual Property and, where
necessary, waiving all moral rights in such Intellectual Property in favour of the Corporation and the Subsidiary, and their successors and assigns; 

  
 - 18 - 

	 	(ddd)	any and all fees or payments required to keep the Corporation IP and the Licensed IP in force or in effect have been timely paid; 

  

	 	(eee)	to the knowledge of the Corporation (including its officers, directors and employees, and the Corporation’s Intellectual Property consultants and managers including Kally Singh), there is no claim of infringement
or breach by the Corporation or the Subsidiary of any industrial or Intellectual Property rights of any other person, nor has the Corporation or the Subsidiary received any notice or threat from any such third party, neither does the Corporation or
its officers, directors and employees, nor the Corporation’s Intellectual Property consultants and managers including Kally Singh, have knowledge that the use of the business names, trademarks, service marks and other industrial or Intellectual
Property of the Corporation or the Subsidiary infringes upon or breaches any industrial or Intellectual Property rights of any other person; 

  

	 	(fff)	there are no Intellectual Property disputes, negotiations, agreements or communications between the Corporation or the Subsidiary and any other persons relating to or potentially relating to the business of the
Corporation or the Subsidiary; 

  

	 	(ggg)	each of the Corporation and the Subsidiary has conducted and is conducting its business in compliance in all material respects with all Applicable Laws of each jurisdiction in which it carries on business and has not
received a notice of non-compliance, nor knows of, nor has reasonable grounds to know of, any facts that could give rise to a notice of non-compliance with any such
laws, regulations or permits which would reasonably be expected to have a Material Adverse Effect; 

  

	 	(hhh)	neither the Corporation nor its officers, directors and employees, and the Corporation’s Intellectual Property consultants and managers including Kally Singh have knowledge of any reason as a result of which the
Corporation or the Subsidiary is not entitled to make use of and commercially exploit the Corporation IP. With respect to each license or agreement by which the Corporation or the Subsidiary has obtained the rights to exploit, in any way, the
Licensed IP rights of any other person or by which the Corporation or the Subsidiary has granted to any third party the right to so exploit such Licensed IP: 

  

	 	(i)	such license or agreement is in full force and effect and is legal, valid, binding and enforceable in accordance with its terms, except to the extent that enforceability may be limited by the Enforceability
Qualifications, and represents the entire agreement between the parties thereto with respect to the subject matter thereof, and no event of default has occurred and is continuing under any such license or agreement; 

 

	 	(ii)	(A) neither the Corporation nor the Subsidiary has received any notice of termination or cancellation under such license or agreement, and no party thereto has any right of termination or cancellation thereunder except
in accordance with its terms; (B) neither the Corporation nor the Subsidiary has received any notice of a breach or default under such license or agreement which breach or default has not been cured; and (C) neither the Corporation nor the
Subsidiary has granted to any other person any rights adverse to, or in conflict with, such license or agreement; and 

  
 - 19 - 

	 	(iii)	neither the Corporation nor its officers, directors and employees, and the Corporation’s Intellectual Property consultants and managers including Kally Singh, have knowledge of any other party to such license or
agreement that is in breach or default thereof, and do not have knowledge of any event that has occurred that, with notice or lapse of time would constitute such a breach or default or permit termination, modification or acceleration under such
license or agreement; 

  

	 	(iii)	no litigation, legal or governmental proceedings or inquiries are in progress or pending to which the Corporation or the Subsidiary is a party or to which their respective businesses, assets and/or properties are
subject which, if the subject of an unfavourable decision, ruling or finding would have a Material Adverse Effect and no such litigation, legal or governmental proceedings or inquiries have been threatened against or, to the Corporation’s
knowledge, are contemplated with respect to the Corporation or the Subsidiary or with respect to their respective businesses, assets and/or properties; 

  

	 	(jjj)	the Corporation is a reporting issuer under Applicable Securities Laws in each of the provinces of British Columbia, Alberta and Ontario; the Corporation is not in default in any material respect of any requirement of
Applicable Securities Laws nor is included in a list of defaulting reporting issuers maintained by the Securities Commissions. In particular, without limiting the foregoing, the Corporation is in compliance at the date hereof with its obligations to
make timely disclosure of all material changes relating to it and, other than in respect of material change reports previously filed on a confidential basis and thereafter made public or material change reports previously filed on a confidential
basis and in respect of which no material change ever resulted, no such disclosure has been made on a confidential basis and there is no material change relating to the Corporation which has occurred and with respect to which the requisite material
change statement has not been filed, except to the extent that the Offering and/or the Concurrent Offering constitute a material change; 

  

	 	(kkk)	for so long as the Warrants and the Broker Warrants remain outstanding, the Corporation shall use its best efforts to comply with its obligations under Applicable Securities Laws, to the extent applicable to it;

  

	 	(lll)	the definitive form of certificate representing the Common Shares complies with the requirements of the Business Corporations Act (British Columbia) and does not conflict with the constating documents of the
Corporation; 

  

	 	(mmm)	the definitive form of Warrant Certificate complies with the requirements of the Business Corporations Act (British Columbia) and does not conflict with the constating documents of the Corporation;

  

	 	(nnn)	there has never been a reportable disagreement (within the meaning of NI 51-102) with the Corporation’s Auditors or, to the knowledge of the Corporation, with the former
auditors of the Corporation; 

  
 - 20 - 

	 	(ooo)	the Corporation maintains a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific
authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets; (iii) access to assets is
permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any
differences; 

  

	 	(ppp)	the composition of the audit committee of the Corporation is in accordance with the requirements of National Instrument 52-110 – Audit Committees; 

 

	 	(qqq)	the Corporation is in compliance with the certification requirements contained in National Instrument 52-109 – Certification of Disclosure in Issuers’ Annual and
Interim Filings with respect to the Corporation’s annual and interim filings with Canadian Securities Commissions; 

  

	 	(rrr)	all disclosure filings required to be made by the Corporation pursuant to the Applicable Securities Laws have been made and such disclosure and filings were true and accurate as at the respective dates thereof, and
there are no material omissions contained therein which would render such disclosure and filings misleading; 

  

	 	(sss)	the Corporation has not declared or paid any dividends or declared or made any other payments or distributions on or in respect of any of its Common Shares and has not, directly or indirectly, redeemed, purchased or
otherwise acquired any of the Common Shares or agreed to do so or otherwise effected any return of capital with respect to such shares; 

  

	 	(ttt)	the Corporation has, and to the best of the Corporation’s knowledge, the directors and officers of the Corporation have, answered every question or inquiry of the Agent and the Agent’s counsel in connection
with the Agent’s due diligence investigations fully and truthfully; 

  

	 	(uuu)	from the effective date of the Corporation’s engagement of the Agent and until the Closing Time and the Over-Allotment Option Closing Time, the Corporation has allowed, and shall continue to allow, the Agent the
opportunity to conduct all required due diligence and to obtain, acting reasonably, satisfactory results therefrom and in particular, the Corporation shall allow the Agent and Agent’s counsel to conduct all due diligence which the Agent may
reasonably require and, in this regard, the Corporation shall make available its senior management and relevant employees and shall use its reasonable commercial efforts to make available the Corporation’s Auditors to answer any questions which
the Agent may have and to participate in one or more due diligence sessions to be held prior to the Closing Date and Over-Allotment Option Closing Date, as the case may be (all of such sessions referred to as the “Due Diligence
Session”); 

  

	 	(vvv)	the Corporation has provided the Agent with all information reasonably requested by the Agent in connection with the Offering. There is no material fact known to the Corporation that has not been disclosed herein, or to
the Agent on behalf of the investors in connection with the transactions contemplated hereby and which would result in a Material Adverse Effect. The Corporation has not withheld from the Agent any material fact relating to the Corporation or to the
Offering; 

  
 - 21 - 

	 	(www)	to the best of the Corporation’s knowledge it is not aware of any legislation, or proposed legislation (published by a legislative body), which it anticipates will materially and adversely affect the business,
affairs, operations, assets, liabilities (contingent or otherwise) or prospects of the Corporation or the Subsidiary; 

  

	 	(xxx)	neither the Corporation or the Subsidiary has, and to the knowledge of the Corporation, no director, officer, agent, employee or other person associated with or acting on behalf of the Corporation or the Subsidiary has:
(i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or
employee from corporate funds; (iii) violated or is in violation of any provision of the Corruption of Foreign Officials Act (Canada) or similar legislation; or (iv) made any bribe, rebate, payoff, influence payment, kickback or
other unlawful payment; 

  

	 	(yyy)	all clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Corporation or the Subsidiary (collectively “Clinical
Trials”) have been and are being conducted in accordance with all Applicable Laws where such studies and tests are being conducted, including Applicable Laws administered by Regulatory Authorities. Neither the Corporation nor the Subsidiary
has received any notices or written correspondence from any Regulatory Authority with respect to any Clinical Trial requiring the termination or suspension of such Clinical Trial; 

 

	 	(zzz)	the results of the Clinical Trials described in the Prospectus are accurate and complete in all material respects and, to the knowledge of the Corporation, there are no other trials, studies or tests, the results of
which could reasonably call into question the results described or referred to in the Prospectus; and the Corporation has not received any notices or other correspondence from such Regulatory Authorities or any other governmental agency or any other
person requiring the termination, suspension or material modification of any research, pre-clinical and clinical validation studies or other studies and tests that are described in the Prospectus or the
results of which are referred to therein; 

  

	 	(aaaa)	the operations of each of the Corporation and the Subsidiary are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of money laundering statutes, the
rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any government or governmental agency (collectively, the “Money Laundering Laws”) and no action, suit
or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Corporation or the Subsidiary with respect to the Money Laundering Laws is pending, or to the best of the Corporation’s knowledge
threatened; 

  

	 	(bbbb)	neither the Corporation nor the Subsidiary has, directly or indirectly: (i) made or authorized any contribution, payment or gift of funds or property to any official, employee or agent of any governmental agency,
authority or instrumentality of any jurisdiction; or (ii) made any contribution to any candidate for public office, in either case where either the payment or the purpose of such contribution, payment or gift was, is or would be prohibited
under the Canada Corruption of Foreign Public Officials Act (Canada) or the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada) or the rules and regulations promulgated thereunder or under any other legislation of
any relevant jurisdiction covering a similar subject matter applicable to the Corporation or the Subsidiary and their respective operations, and will not use any portion of the gross proceeds, in contravention of such legislation; and

  
 - 22 - 

	 	(cccc)	each of the Corporation and the Subsidiary or, to the best knowledge of the Corporation, any director, officer, agent, employee, affiliate or person acting on behalf of the Corporation or the Subsidiary (other than the
Agent, the U.S. Agent or any members of the banking and selling group formed by them, as to whom the Corporation makes no representation) has not been or is not currently subject to any United States sanctions administered by the Office of Foreign
Assets Control of the United States Treasury Department and the Corporation will not directly or indirectly use any proceeds of the Offering or lend, contribute or otherwise make available such proceeds to the Corporation or the Subsidiary or to any
affiliated entity, joint venture partner or other person or entity, to finance any investments in, or make any payments to, any country or person targeted by any of the sanctions of the United States. 

 

	7.	Covenants of the Corporation 

 The Corporation covenants and agrees with the Agent as
follows: 
  

	 	(a)	the Corporation will use commercially reasonable efforts to maintain its status as a reporting issuer not in default in each of the Public Selling Jurisdictions in which it is a reporting issuer or the equivalent for a
period of at least 60 months following the final Closing Date, provided that the foregoing requirement is subject to the obligations of the directors of the Corporation to comply with their fiduciary duties to the Corporation; 

 

	 	(b)	the Corporation shall forthwith advise the Agent of, and provide the Agent with copies of, any written communications relating to: 

  

	 	(i)	the issuance by any securities regulatory authority, including the TSXV or NASDAQ, of any order suspending or preventing the use of the Prospectus or any cease trading or stop order or any halt in trading relating to
the Common Shares or the institution or threat of any proceedings for that purpose; and 

  

	 	(ii)	the receipt of any material communication from any securities regulatory authority, including the TSXV and NASDAQ, or other authority relating to the Prospectus or the Offering; 

 

	 	(c)	the Corporation shall use its commercially reasonable best efforts to maintain the listing of the Common Shares on the TSXV and the NASDAQ or such other recognized stock exchange or quotation system as the Agent may
approve, acting reasonably, for as long as any Warrants or Broker Warrants remain outstanding, other than in a business combination or similar transaction where all the outstanding securities of the Corporation have been exchanged for cash or the
securities of another issuer which is a reporting issuer under any Applicable Securities Laws; 

  

	 	(d)	the Corporation shall use its commercially reasonable efforts to ensure that the Shares will be conditionally approved for listing on the TSXV upon their issue; 

 

	 	(e)	the Corporation shall use the net proceeds of the Offering contemplated herein in the manner and subject to the qualifications described in the Prospectus under the heading “Use of Proceeds”;

  
 - 23 - 

	 	(f)	the Corporation will make all filings necessary with each applicable Securities Commission and pay all applicable fees in connection with the Offering in full compliance with the manner and within the time limits
prescribed by Applicable Securities Laws; 

  

	 	(g)	the Corporation shall duly, faithfully and punctually perform all the obligations to be performed by it and comply with its covenants and agreements hereunder and under the Transaction Documents; 

 

	 	(h)	with a view to making available to the investors the benefits of Rule 144 under the 1933 Act (“Rule 144”) or any other similar rule or regulation of the SEC that may at any time permit the investors to
sell securities of the Corporation to the public without registration and otherwise to facilitate liquidity for trading in the United States, the Corporation agrees to: 

 

	 	(i)	make public information available, as those terms are understood and defined in Rule 144; 

  

	 	(ii)	file with the SEC in a timely manner all reports and other documents required of the Corporation under the 1934 Act; and 

  

	 	(iii)	so long as any of the investors own Offered Shares, Warrants or Warrant Shares that may not be sold pursuant to Rule 144 without compliance with the current public information requirement thereof, (i) furnish to
the investors a written statement by the Corporation that it has complied with the reporting requirements of the 1934 Act as required for applicable provisions of Rule 144, (ii) furnish or otherwise make available (on EDGAR or otherwise) a copy of
the most recent annual or quarterly report of the Corporation and such other reports and documents so filed by the Corporation and (iii) furnish or otherwise make available such other information as may be reasonably requested to permit the
investors to sell such securities pursuant to Rule 144 without registration under the 1933 Act; 

  

	 	(i)	the Corporation shall use its reasonable best efforts to cause the Shares to be listed for trading on the TSXV as soon as possible following the Closing. Subsequent to a listing of such securities on the TSXV, the
Corporation shall use its reasonable best efforts to maintain such listing for a period of 60 months following the final Closing Date. The Corporation shall take all such actions as shall be necessary to effectuate such listing and the maintenance
thereof. The Corporation shall pay all fees and expenses in connection with satisfying its obligations under this subsection 7(i); 

  

	 	(j)	from and after the filing of the press release announcing the Closing, no investor shall be in possession of any material, nonpublic information received from the Corporation, the Subsidiary or any of their respective
officers, directors, employees or agents, that is not disclosed in the press release announcing the Closing. The Corporation shall not, and shall cause the Subsidiary and its and each of their respective officers, directors, employees and agents,
not to, provide any investor with any material, nonpublic information regarding the Corporation or the Subsidiary from and after the filing of the press release announcing the Closing without the express written consent of such investor. In the
event of a breach of any of the foregoing covenants by the Corporation, the Subsidiary or any of its or their respective officers, directors, employees and agents (as determined in the reasonable good faith judgment of such investor), in addition to
any other remedy provided herein or available at law or in equity, such investor shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such breach or such material, nonpublic
information, as applicable, without the prior approval by the Corporation, the Subsidiary or any of its or their respective officers, directors, employees or agents. No investor shall have any liability to the Corporation, the Subsidiary, or any of
its or their respective officers, directors, employees, stockholders or agents, for any such disclosure; and 

  
 - 24 - 

	 	(k)	for each taxable year of the Corporation that the Corporation determines that it, and any subsidiary in which the Corporations owns, directly or indirectly, more than 50% of such subsidiary’s total aggregate voting
power, is likely a passive foreign investment company under the United States Internal Revenue Code of 1986 in any taxable year, the Corporation will make available to a holder that owns any Offered Shares, Warrants or Warrant Shares, upon written
request and in accordance with applicable procedures, a “PFIC Annual Information Statement” with respect to the Corporation and any such subsidiary for such taxable year. 

 

	8.	Agent’s Compensation 

  

	 	(a)	In consideration for the Agent’s services hereunder, the Corporation agrees to pay to the Agent a fee equal to 7% of the gross proceeds of the Offering (excluding subscriptions from the Partially Excluded
Purchasers who, prior to the public announcement of the Offering, delivered a written indication of interest identifying the definitive level of proceeds such Partially Excluded Purchaser will purchase in the Offering, in which case shall attract a
fee equal to 3.5% of the gross proceeds) payable in cash on any Closing Date and Over-Allotment Option Closing Date, as the case may be, (the “Agency Fee”). For certainty, the Corporation shall not be responsible for paying any fees
or expenses of the U.S. Agent, which fees and expenses shall be the sole responsibility of the Agent. 

  

	 	(b)	As additional consideration for the Agent’s services performed under this Agreement, the Corporation shall issue to the Agent on any Closing Date and Over-Allotment Option Closing Date, as the case may be, broker
warrants (the “Broker Warrants”) exercisable to purchase, at an exercise price equal to the Offering Price, at any time until 4:30 p.m. (Toronto Time) on or before the date which is 60 months after the date of issuance thereof, that
number of Broker Shares as is equal to 5% of the aggregate of the number of Offered Securities sold pursuant to the Offering (excluding Offered Securities purchased by the Partially Excluded Purchasers) at the Offering Price. 

 

	9.	Closing 

  

	 	(a)	The purchase and sale of the Offered Securities shall be completed at the Closing Time at the offices of counsel to the Corporation, or at such other place or places as the Agent and the Corporation may agree. At the
Closing Time, the Corporation shall (a) deliver to the Agent one or more global certificates representing the Offered Shares and Warrants, respectively, sold pursuant to the Offering registered in the name of CDS, or otherwise effect or cause
to be effected one or more electronic deposit(s) pursuant to the non-certificated issue system maintained by CDS such quantity of Offered Securities as the Agent may direct the Corporation in writing, and
(b) with respect to U.S. Investors, deliver to the Agent physical certificates bearing U.S. restrictive legends representing the Offered Shares and Warrants registered as the Agent may direct the Corporation in writing, against payment by the
Agent to the Corporation of the aggregate purchase price payable to the Corporation for the Offered Securities by certified cheque, bank draft or wire transfer. The payment made to the Corporation will be net of the Agency Fee and net of amounts
payable to the Agent’s legal counsel, Baker & McKenzie LLP, and out-of-pocket expenses of the Agent incurred in connection with the Offering (which
expenses shall be borne by the Corporation), as more fully set out in Section 15. In addition, the Corporation shall, at the Closing Time, issue to the Agent (or as the Agent may direct) the Broker Warrant Certificates. 

  
 - 25 - 

	 	(b)	The purchase and sale of the Additional Securities shall be completed at the Over-Allotment Option Closing Time at the offices of counsel to the Corporation, or at such other place or places as the Agent and the
Corporation may agree. At the Over-Allotment Option Closing Time, the Corporation shall (a) deliver to the Agent one or more global certificates representing the Additional Shares and Additional Warrants, respectively, sold pursuant to the
Offering registered in the name of CDS, or otherwise effect or cause to be effected one or more electronic deposit(s) pursuant to the non-certificated issue system maintained by CDS such quantity of Additional
Securities the Agent may direct the Corporation in writing, and (b) with respect to U.S. Investors, deliver to the Agent physical certificates bearing U.S. restrictive legends representing the Additional Shares and Additional Warrants
registered as the Agent may direct the Corporation in writing, against payment by the Agent to the Corporation of the aggregate purchase price payable to the Corporation for the Additional Securities by certified cheque, bank draft or wire transfer.
The payment made to the Corporation will be net of the Agency Fee and net of amounts payable to the Agent’s legal counsel, Baker & McKenzie LLP, and
out-of-pocket expenses of the Agent incurred in connection with the exercise of the Over-Allotment Option (which expenses shall be borne by the Corporation), as more
fully set out in Section 15. In addition, the Corporation shall, at the Over-Allotment Option Closing Time, issue to the Agent (or as the Agent may direct) the Broker Warrant Certificates associated with the Over-Allotment Option.

  

	10.	Closing Conditions 

 The Agent’s obligation to complete the Closing at the Closing Time and the
Over-Allotment Option Closing Time (which, for greater, certainty, shall mean the Closing of each tranche of the Offering if the Offering is completed in more than one tranche), shall be subject to the accuracy of the representations and warranties
of the Corporation contained in this Agreement as of the date of this Agreement, as of the Closing Date and as of the Over-Allotment Option Closing Date, as the case may be, and performance by the Corporation of its obligations under this Agreement
in all material respects and the following conditions: 
  

	 	(a)	The Agent shall have received at the Closing Time and Over-Allotment Option Closing Time as the case may be, a legal opinion dated the Closing Date and Over-Allotment Option Closing Date, as the case may be, in form and
substance satisfactory to counsel to the Agent, addressed to the Agent and counsel to the Agent from counsel to the Corporation, Blake, Cassels & Graydon LLP and any other local counsel, acting reasonably (it being understood that such
counsel may rely to the extent appropriate in the circumstance: (i) as to matters of fact, on certificates of the Corporation executed on its behalf by a senior officer of the Corporation and on certificates of the Transfer Agent, as to the
issued capital of the Corporation; and (ii) as to matters of fact not independently established, on certificates of public officials) with respect to the following matters (with such opinions being subject to usual and customary assumptions and
qualifications, including the qualifications set out below): 

  

	 	(i)	as to the incorporation and subsistence of the Corporation under the laws of the Province of British Columbia and as to the corporate power of the Corporation to carry out its obligations under this Agreement and to
issue the Offered Securities and the Broker Warrants; 

  
 - 26 - 

	 	(ii)	as to the authorized and issued capital of the Corporation; 

  

	 	(iii)	that the Corporation has all requisite corporate power and authority under the laws of its jurisdiction of incorporation to carry on its business and to own or lease its properties and assets as described in the
Prospectus; 

  

	 	(iv)	that none of the execution and delivery of the Transaction Documents and the performance by the Corporation of its obligations hereunder, or the sale or issuance of the Offered Securities and the Broker Warrants will
conflict with or result in any breach of the articles or by-laws of the Corporation; 

  

	 	(v)	that each of the Transaction Documents has been duly authorized and executed and delivered by the Corporation, and constitutes a valid and legally binding obligation of the Corporation enforceable against it in
accordance with its terms, except as enforcement thereof may be limited by the Enforceability Qualifications; 

  

	 	(vi)	all necessary corporate action has been taken by the Corporation to authorize the execution and delivery of the Prospectus and the filing of such documents as are required under Applicable Securities Laws in each of the
Canadian Selling Jurisdictions; 

  

	 	(vii)	that the Offered Shares have been validly issued as fully paid and non-assessable securities in the capital of the Corporation; 

 

	 	(viii)	that each of the Warrants and Broker Warrants have been duly and validly created and issued; 

  

	 	(ix)	that the Warrant Shares have been authorized and allotted for issuance and, upon the issuance of the Warrant Shares following due exercise of the Warrants in accordance with the respective terms thereof, the Warrant
Shares will be validly issued as fully paid and non-assessable securities in the capital of the Corporation; 

  

	 	(x)	that the Broker Shares have been authorized and allotted for issuance and, upon the issuance of the Broker Shares following due exercise of the Broker Warrants in accordance with the respective terms thereof, the Broker
Shares will be validly issued as fully paid and non-assessable securities in the capital of the Corporation; 

  
 - 27 - 

	 	(xi)	all approvals, permits, consents, orders and authorizations have been obtained, all necessary documents have been filed and all other legal requirements have been fulfilled under Applicable Securities Laws of the
Canadian Selling Jurisdictions to qualify the issuance or Distribution and sale of the Offered Securities to the public in each of the Canadian Selling Jurisdictions and the Broker Warrants to the Agent and to permit the issuance, sale and delivery
of the Offered Securities to the public through dealers registered under the Applicable Laws of each of the Canadian Selling Jurisdictions who have complied with the relevant provisions of such laws and the terms of their registration;

  

	 	(xii)	subject to the qualifications, assumptions, limitations and understandings set out therein, the statements set out in the Prospectus, under the headings “Certain Canadian Federal Income Tax Considerations” and
“Eligibility for Investment” are true and correct as at the date of the Prospectus; 

  

	 	(xiii)	that the attributes of each of the Common Shares and Warrants conform in all material respects with the description thereof contained in the Prospectus; 

 

	 	(xiv)	that the Offering and the listing of the Shares has been conditionally accepted by the TSXV; and 

  

	 	(xv)	as to such other matters as the Agent’s legal counsel may reasonably request prior to the Closing Time and Over-Allotment Option Closing Time, as the case may be; 

 

	 	(b)	The Agent shall have received at the Closing Time and Over-Allotment Option Closing Time as the case may be, a legal opinion dated the Closing Date and Over-Allotment Option Closing Date, as the case may be, in form and
substance satisfactory to counsel to the Agent, addressed to the Agent, from local counsel in the jurisdiction of incorporation of the Subsidiary, with respect to the following matters: 

 

	 	(i)	the incorporation and existence of the Subsidiary under the laws of its jurisdiction of incorporation; 

  

	 	(ii)	as to the registered ownership of the issued and outstanding shares of the Subsidiary; and 

  

	 	(iii)	that the Subsidiary has all requisite corporate power under the laws of its jurisdiction of incorporation to carry on its business as presently carried on and own or lease its properties and assets; 

 

	 	(c)	The Agent shall have received at the Closing Time and the Over-Allotment Option Closing Time as the case may be, certificates dated the Closing Date and Over-Allotment Option Closing Date, as the case may be, addressed
to the Agent and counsel to the Agent and signed by appropriate officers of the Corporation, with respect to the constating documents of the Corporation, all resolutions of the board of directors of the Corporation (including any committees thereof)
relating to the Transaction Documents, the incumbency and specimen signatures of signing officers of the Corporation and with respect to such other matters as the Agent may reasonably request; 

 

	 	(d)	The Agent shall have received at the Closing Time and the Over-Allotment Option Closing Time as the case may be, a certificate dated the Closing Date and the Over-Allotment Option Closing Date, as the case may be,
addressed to the Agent and counsel to the Agent and signed on behalf of the Corporation by the Chief Executive Officer and the Chief Financial Officer of the Corporation or other officers of the Corporation acceptable to the Agent, certifying for
and on behalf of the Corporation after having made due enquiry, that: 

  

	 	(i)	there are no contingent liabilities affecting the Corporation which are material to the Corporation; 

  
 - 28 - 

	 	(ii)	the Corporation has complied with and satisfied in all material respects the covenants, terms and conditions of this Agreement on its part to be complied with and satisfied up to the Closing Time and the Over-Allotment
Option Closing Time as the case may be; 

  

	 	(iii)	the representations and warranties of the Corporation contained in the Transaction Documents are true and correct in all material respects as of the Closing Time and the Over-Allotment Option Closing Time as the case
may be with the same force and effect as if made at and as of the Closing Time and the Over-Allotment Option Closing Time as the case may be after giving effect to the transactions contemplated by this Agreement; 

 

	 	(iv)	the Corporation has made and/or obtained on or prior to the Closing Time and the Over-Allotment Option Closing Time as the case may be, all necessary filings, approvals, consents and acceptances of applicable regulatory
authorities and under any applicable agreement or document to which the Corporation is a party or by which it is bound, required for the execution and delivery of the Transaction Documents, the offering and sale of the Offered Securities and the
consummation of the other transactions contemplated by this Agreement (subject to completion of filings with certain regulatory authorities following the Closing Date and the Over-Allotment Option Closing Date, as the case may be);

  

	 	(v)	no order, ruling or determination having the effect of suspending the sale of the Offered Securities has been issued by any regulatory authority and is continuing in effect and no proceedings for that purpose have been
instituted or are pending or, to the knowledge of such officer of the Corporation, contemplated or threatened under any Applicable Securities Laws or by any other regulatory authority; and 

 

	 	(vi)	such other matters as the Agent may reasonably request; 

  

	 	(e)	The Corporation will have made and/or obtained the necessary filings, approvals, consents and acceptances of the appropriate regulatory authorities required to be made or obtained by the Corporation in connection with
the sale of the Offered Securities in the Selling Jurisdictions prior to the Closing Time and the Over-Allotment Option Closing Time as the case may be as herein contemplated; 

 

	 	(f)	The Agent shall have received confirmation from the Corporation that the Corporation is not on the defaulting issuer’s list (or equivalent) maintained by the Securities Commissions in each jurisdiction in which the
Corporation is a reporting issuer; 

  

	 	(g)	The Corporation shall not have received any notice from the TSXV or NASDAQ, if applicable, that any of the Shares shall not be accepted for listing on the TSXV or NASDAQ respectively; 

  
 - 29 - 

	 	(h)	The Agent and its counsel shall have been provided with all information and documentation reasonably requested relating to their due diligence inquiries and investigations; and 

 

	 	(i)	If any of the Offered Securities are purchased by U.S. Investors, the Agent shall have received at the Closing Time and the Over-Allotment Option Closing Time, as the case may be, a legal opinion, in form and substance
satisfactory to the Agent, acting reasonably, addressed to the Agent from U.S. counsel to the Corporation, and based upon such assumptions as are reasonable, to the effect that registration under the 1933 Act is not required in connection with the
offer or sale of the Offered Shares and Warrants in the United States. 

  

	11.	All Terms to be Conditions 

 The Corporation agrees that the conditions contained in this Agreement,
including those terms in Section 10, will be construed as conditions and any breach or failure to comply with any of the conditions shall entitle the Agent to terminate its obligations hereunder by written notice to that effect given to the
Corporation at or prior to the Closing Time. It is understood that the Agent may waive, in whole or in part, or extend the time for compliance with, any of such terms and conditions without prejudice to the rights of the Agent in respect of any such
terms and conditions or any other or subsequent breach or non-compliance of the Corporation, provided that to be binding on the Agent, any such waiver or extension must be in writing and signed by the Agent.

  

	12.	Rights of Termination 

 This Agreement may be terminated in the sole discretion of the Agent by written
notice to the Corporation given prior to the Closing Time in the event that: 
  

	 	(a)	the Corporation is in material breach of any term, condition, covenant or agreement contained in this Agreement or any representation or warranty given by the Corporation in this Agreement is determined to have been
untrue, false or misleading in any material way as of the date upon which such was given; or 

  

	 	(b)	prior to the Closing Time: 

  

	 	(i)	there shall have occurred any adverse material change or there shall be discovered any previously undisclosed adverse material fact in relation to the Corporation; or 

 

	 	(ii)	there shall have occurred any change in Applicable Securities Laws or any inquiry, investigation or other proceeding is made or any order is issued under or pursuant to any statute of Canada or any province thereof or
any regulatory authority in relation to the Corporation or any of its securities (except for any inquiry, investigation or other proceeding based upon activities of the Agent and not upon activities of the Corporation); 

which, in the reasonable opinion of the Agent, prevents or restricts trading in the Shares or the distribution of the Offered Securities; or

  
 - 30 - 

	 	(iii)	there should develop, occur or come into effect or existence any event, action, state, condition or major financial occurrence or catastrophe of national or international consequence or any law or regulation or a change
thereof which, in the reasonable opinion of the Agent, materially adversely affects or involves, or will materially adversely affect or involve, the financial markets or the business, operations or affairs of the Corporation, taken as a whole;

  

	 	(iv)	the state of the financial markets in Canada and the United States is such that, in the reasonable opinion of the Agent, the Offered Securities cannot be marketed profitably; 

 

	 	(v)	there is an inquiry or investigation (whether formal or informal) by any securities regulator or other regulatory authority in relation to the Corporation or any one of its directors or officers, or any of its principal
shareholders, which has not been rescinded, revoked or withdrawn and which, in each case, operates to materially prevent or restrict the Distribution of the Offered Securities as contemplated by this Agreement; 

 

	 	(vi)	a cease trading order with respect to any securities of the Corporation is made by any securities regulator or other competent authority by reason of the fault of the Corporation or its directors, officers and agents
and such cease trading order has not been rescinded, revoked or withdrawn; 

  

	 	(vii)	the Agent, acting reasonably, is not satisfied in its sole discretion with its due diligence review and investigations; or 

  

	 	(viii)	the Corporation receives notice from the TSXV that any of the Shares shall not be accepted for listing on the TSXV. 

The rights of termination contained in this Section 12 are in addition to any other rights or remedies the Agent may have in respect of any default, act
or failure to act or non-compliance by the Corporation in respect of any of the matters contemplated by this Agreement or otherwise. In the event of any such termination, there shall be no further liability on
the part of the Agent to the Corporation or on the part of the Corporation to the Agent except in respect of any liability which may have arisen prior to or arise after such termination under any of Sections 13 and 15. 

 

	13.	Indemnity 

 The Corporation agrees to indemnify and save harmless the Agent and the U.S. Agent and their
affiliates, and each of their respective directors, officers, employees, shareholders, partners, agents and advisors (collectively, the “Indemnified Parties” and each, an “Indemnified Party”), from and against any
and all losses (except loss of profit), claims, actions, suits, proceedings, damages, liabilities or expenses of whatsoever nature or kind, including the aggregate amount paid in reasonable settlement of any actions, suits, proceedings,
investigations or claims and the reasonable, actual and accountable fees and expenses of their counsel in connection with any action, suit, proceeding, investigation or claim that may be made or threatened against any Indemnified Party or in
enforcing this indemnity (collectively, the “Claims”) to which an Indemnified Party may become subject or otherwise involved in any capacity insofar as the Claims relate to, are caused by, result from, arise out of or are based
upon, directly or indirectly, the performance of professional services rendered to the Corporation by an Indemnified Party hereunder or otherwise in connection with the matters referred to in this Agreement, whether performed before or after the
Corporation’s execution of this Agreement, and further agrees to immediately reimburse each Indemnified Party forthwith, upon demand, for any legal or other expenses reasonably incurred by such Indemnified Party in connection with any Claim.

  
 - 31 - 

 The Corporation also agrees that no Indemnified Party shall have any liability (either direct or indirect, in
contract or tort or otherwise) to the Corporation or any person asserting Claims on the Corporation’s behalf or in right for or in connection with the performance of professional services rendered to the Corporation by an Indemnified Party
hereunder or otherwise in connection with the matters referred to in this Agreement, whether performed before or after the Corporation’s execution of the Agreement, except to the extent that any losses, expenses, Claims, actions, damages or
liabilities incurred by the Corporation are determined by a court of competent jurisdiction in a final judgement that has become non-appealable to have resulted from the Indemnified Party’s breach of this
Agreement, or the gross negligence, wilful misconduct or fraud of such Indemnified Party. 
 In the event and to the extent that a court of competent
jurisdiction in a final judgement that has become non-appealable determines that an Indemnified Party breached this Agreement, or was grossly negligent or guilty of wilful misconduct or fraud in connection
with a Claim in respect of which the Corporation has advanced funds to the Indemnified Party pursuant to this indemnity, such Indemnified Party shall immediately reimburse such funds to the Corporation and thereafter this indemnity shall not apply
to such Indemnified Party in respect of such Claim. 
 The Corporation agrees to waive any right the Corporation might have of first requiring the
Indemnified Party to proceed against or enforce any other right, power, remedy or security or claim payment from any other person before claiming under this indemnity. 

In case any Claim is brought against an Indemnified Party, or an Indemnified Party has received notice of the commencement of any investigation in respect of
which indemnity may be sought against the Corporation, the Indemnified Party will give the Corporation prompt written notice of any such Claim or investigation of which the Indemnified Party has knowledge and the Corporation will undertake the
investigation and defence thereof on behalf of the Indemnified Party, including the prompt employment of counsel acceptable to the Indemnified Parties affected and the payment of all expenses. Failure by the Indemnified Party to so notify shall not
relieve the Corporation of its obligation of indemnification hereunder unless (and only to the extent that) such failure results in the forfeiture by the Corporation of substantive rights or defences or the extent that the Corporation is materially
prejudiced thereby. 
 No admission of liability and no settlement, compromise or termination of any Claim shall be made without the Corporation’s
consent and the consent of the Indemnified Parties affected, such consents not to be unreasonably withheld. 
 Notwithstanding that the Corporation will
undertake the investigation and defence of any Claim, an Indemnified Party will have the right to employ separate counsel with respect to any Claim and participate in the defence thereof, but the fees and expenses of such counsel will be at the
expense of the Indemnified Party unless: 
  

	 	(a)	the employment of such counsel has been authorized in writing by the Corporation; 

  

	 	(b)	the Corporation has not assumed the defence within a reasonable period of time after receiving notice of such Claim; 

  

	 	(c)	the named parties to any such Claim include both the Corporation and the Indemnified Party and the Indemnified Party shall have been advised by counsel in writing that there may be a conflict of interest between the
Corporation and the Indemnified Party; or 

  

	 	(d)	the Indemnified Party has been advised in writing by counsel that there are one or more defences available to the Indemnified Party which are different from or in addition to those available to the Corporation, which
makes representation by the same counsel inappropriate. 

  
 - 32 - 

 The rights accorded to the Indemnified Parties hereunder shall be in addition to any rights an Indemnified Party
may have at common law or otherwise. 
 If for any reason the foregoing indemnification is unavailable (other than in accordance with the terms hereof) to
the Indemnified Parties (or any of them) or insufficient to hold them harmless, then the Corporation shall contribute to the amount paid or payable by the Indemnified Parties as a result of such Claim in such proportion as is appropriate to reflect
not only the relative benefits received by the Corporation on the one hand and the Indemnified Parties on the other hand, but also the relative fault of the Corporation and the Indemnified Parties, as well as any other equitable considerations which
may be relevant; provided that the Corporation shall, in any event, contribute to the amount paid or payable by the Indemnified Parties as a result of such Claim, any amount in excess of the fees actually received by the Indemnified Parties
hereunder in which case such fees and expenses will be for the Corporation’s account. 
 The Corporation hereby acknowledges the Agent as trustee for
each of the other Indemnified Parties of the Corporation’s covenants under this indemnity with respect to such persons and the Agent agrees to accept such trust and to hold and enforce such covenants on behalf of such persons. 

The Corporation agrees to immediately reimburse the Agent monthly for the time spent by an Indemnified Party in connection with any Claim at their reasonable
per diem rates. The Corporation also agrees that if any Claim shall be brought against, or an investigation commenced in respect of the Corporation or the Corporation and the Indemnified Parties shall be required to testify, participate or respond
in respect of or in connection with the performance of professional services rendered to the Corporation by an Indemnified Party hereunder or otherwise in connection with the matters referred to in this Agreement, the Agent shall have the right to
employ its own counsel in connection therewith and the Corporation will immediately reimburse the Agent monthly for the time spent by an Indemnified Party in connection therewith at their reasonable per diem rates together with such fees and
disbursements and reasonable, actual and accountable expenses as may be incurred, including the fees and disbursements of the Agent’s counsel. 
  

	14.	Severability 

 If any provision of this Agreement is determined to be void or unenforceable in whole or
in part, it shall be deemed not to affect or impair the validity of any other provision of this Agreement and such void or unenforceable provision shall be severable from this Agreement. 

 

	15.	Expenses 

 Out of the proceeds of the Offering, the Corporation shall pay all expenses and fees in
connection with the Offering, including all expenses of or incidental to the issue, sale or Distribution of the Offered Securities; the fees and expenses of the Corporation’s counsel; and all costs incurred in connection with the preparation of
documents relating to the Offering. The Corporation shall also pay all legal expenses and fees incurred by the Agent, which shall include the reasonable fees of Baker & McKenzie LLP, counsel for the Agent and U.S. Agent, up to a maximum of
US$75,000 plus disbursements and taxes, and all reasonable out-of-pocket expenses of the Agent provided that such costs claimed by the Agent shall not exceed US$25,000
plus disbursements and taxes. However, that such reimbursement amount in no way limits or impairs the indemnification and contribution provisions of this Agreement. In the event the Closing does not occur, all fees and expenses incurred by the Agent
shall be payable by the Corporation immediately upon receiving an invoice therefor from the Agent. 

  
 - 33 - 

	16.	Survival of Representations and Warranties 

 The representations, warranties, covenants, obligations and
agreements of the Corporation contained in this Agreement and in any certificate delivered pursuant to this Agreement or in connection with the purchase and sale of the Offered Securities shall survive the purchase of the Offered Securities and
shall continue in full force and effect for a period of three years following the Closing Date regardless of any subsequent disposition of the Offered Securities by the investors or the termination of the Agent’s obligations and shall not be
limited or prejudiced by any investigation made by or on behalf of the Agent in connection with the sale of the Offered Securities. 
  

	17.	Conflict of Interest 

 The Corporation acknowledges that the Agent and its affiliates carry on a range of
businesses, including providing stockbroking, investment advisory, research, investment management and custodial services to clients and trading in financial products as agent or principal. It is possible that the Agent and other entities in its
group that carry on those businesses may hold long or short positions in securities of companies or other entities, which are or may be involved in the transactions contemplated in this Agreement and effect transactions in those securities for their
own account or for the account of their respective clients. The Corporation agrees that these divisions and entities may hold such positions and effect such transactions without regard to the Corporation’s interests under this Agreement. 

 

	18.	Time of the Essence 

 Time shall be of the essence of this Agreement. 

 

	19.	Fiduciary 

 The Corporation hereby acknowledges that the Agent is acting solely as agent in connection
with the offer and sale of the Offered Securities. The Corporation further acknowledges that the Agent is acting pursuant to a contractual relationship created solely by this Agreement entered into on an arm’s length basis, and in no event do
the parties intend that the Agent act or be responsible as a fiduciary to the Corporation, its management, shareholders or creditors or any other person in connection with any activity that the Agent may undertake or have undertaken in furtherance
of such offer and sale of the Corporation’s securities, either before or after the date hereof. The Agent hereby expressly disclaims any fiduciary or similar obligations to the Corporation, either in connection with the transactions
contemplated by this Agreement or any matters leading up to such transactions, and the Corporation hereby confirms its understanding and agreement to that effect. The Corporation and the Agent agree that they are each responsible for making their
own independent judgments with respect to any such transactions and that any opinions or views expressed by the Agent to the Corporation regarding such transactions, including any opinions or views with respect to the price or market for the
Corporation’s securities, do not constitute advice or recommendations to the Corporation. The Corporation and the Agent agree that the Agent is acting as principal and not the agents or fiduciaries of the Corporation and the Agent has not, and
the Agent will not assume, any advisory responsibility in favour of the Corporation with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the
Corporation on other matters). The Corporation hereby waives and releases, to the fullest extent permitted by law, any claims that the Corporation may have against the Agent with respect to any breach or alleged breach of any fiduciary duty to the
Corporation in connection with the transactions contemplated by this Agreement. 

  
 - 34 - 

	20.	Governing Law 

 This Agreement shall be governed by and construed in accordance with the laws of British
Columbia and the laws of Canada applicable in British Columbia and the parties hereto irrevocably attorn to the jurisdiction of the courts of such province. 
  

	21.	Funds 

 Unless otherwise specified, all funds referred to in this Agreement shall be in Canadian dollars.

  

	22.	Stipulation for the Benefit of U.S. Agent 

 The Corporation and the Agent acknowledge and agree that H.C.
Wainwright & Co. LLC will act as the U.S. Agent for the Offering. The Corporation hereby covenants and agrees, for the benefit of H.C. Wainwright & Co. LLC, that H.C. Wainwright & Co. LLC will be entitled to benefit from
and rely on, to the same extent as the Agent, all the representations and warranties, covenants and indemnification undertakings of the Corporation contained in this Agreement for the benefit of the Agent. Furthermore, each document which the
Corporation must address and deliver to the Agent under the Agreement shall also be addressed and delivered to H.C. Wainwright & Co. LLC concurrently with the delivery thereof to the Agent. 

 

	23.	Notice 

 Unless otherwise expressly provided in this Agreement, any notice or other communication to be
given under this Agreement (a “Notice”) shall be in writing addressed as follows: 
 If to the Corporation, addressed and
sent to: 
 ESSA Pharma Inc. 

999 West Broadway, Suite 720 

Vancouver, BC V5Z 1K5 

Attention:    David Parkinson, Chief Executive Officer 

Fax:            
 604-738-4080 
 with a copy (which shall not constitute notice) to: 

Blake, Cassels & Graydon LLP 

599 Burrard Street, Suite 2600 

Vancouver, BC V7X 1L3 

Attention:    Joseph Garcia 

Fax:            
 604-631-3307 
 If to the Agent, addressed and sent to: 

Bloom Burton Securities Inc. 

65 Front Street East, Suite 300 

Toronto, ON M5E 1B5 

Attention: Jolyon Burton 

Email: jburton@bloomburton.com 

  
 - 35 - 

 with a copy (which shall not constitute notice) to: 

Baker & McKenzie LLP 

Brookfield Place 
 181 Bay
Street, Suite 2100 
 Toronto, ON M5J 2T3 

Attention:     Sonia Yung 

Fax:
             416-863-6275 

or to such other address as any of the persons may designate by Notice given to the others. 

Each Notice shall be personally delivered to the addressee or sent by fax to the addressee and (i) a Notice which is personally delivered shall, if
delivered on a Business Day, be deemed to be given and received on that day and, in any other case, be deemed to be given and received on the first Business Day following the day on which it is delivered; and (ii) a Notice which is sent by fax
shall be deemed to be given and received on the first Business Day following the day on which it is sent. 
  

	24.	Entire Agreement 

 The provisions herein and schedules attached hereto contained constitute the entire
agreement between the parties relating to the Offering and supersede all previous communications, representations, understandings and agreements between the parties with respect to the subject matter hereof whether verbal or written, including the
Original A&R Agreement. 
  

	25.	Assignment 

 Except as contemplated herein, no party hereto may assign this Agreement or any part hereof
without the prior written consent of the other parties hereto. Subject to the foregoing, this Agreement shall enure to the benefit of, and shall be binding upon, the Corporation and the Agent and their successors and legal representatives, and
nothing expressed or mentioned in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement, or any provisions contained in this Agreement, this
Agreement and all conditions and provisions of this Agreement being intended to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person except that the covenants and indemnities of the Corporation set
out under the heading “Indemnity” shall also be for the benefit of the Indemnified Parties. 
  

	26.	Press Releases 

 Any press release connected with the Offering issued by the Corporation shall be issued
only after consultation with the Agent. If the Offering is successfully completed, the Agent shall be permitted only after consultation with the Corporation, to publish, at the Agent’s expense, and in compliance with Applicable Securities Laws
such advertisements or announcements relating to the services provided hereunder in such newspaper or other publications as they may consider appropriate. 

  
 - 36 - 

	27.	Counterparts 

 This Agreement may be executed by any one or more of the parties to this Agreement in any
number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. 
  

	28.	Language 

 The parties hereto confirm their express wish that this agreement and all documents and
agreements directly or indirectly relating thereto be drawn up in the English language. 
 Les parties reconnaissent leur volonté express que la
présente convention ainsi que tous les documents et contrats s’y rattachant directement ou indirectement soient rédigés en anglais. 
  

	29.	Facsimile or Electronic Transmission 

 The Corporation and the Agent shall be entitled to rely on
delivery by facsimile or other electronic means of an executed copy of this Agreement and acceptance by the Corporation and the Agent of that delivery shall be legally effective to create a valid and binding agreement between the Corporation and the
Agent in accordance with the terms of this Agreement. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 - 37 - 

 If the foregoing is in accordance with your understanding and is agreed to by you, please signify your acceptance
by executing this letter where indicated below and returning the same to the Agent upon which this letter as so accepted shall constitute an agreement among us. 

 

			
	Yours very truly,
	
	BLOOM BURTON SECURITIES INC.
		
	Per:	 	 /s/ Jolyon
Burton                    

	Name:	 	Jolyon Burton
	Title:	 	President and Head of Investment Banking
	
	Authorized Signing Officer

 The foregoing offer is accepted and agreed to as of the date first above written. 

 

			
	ESSA PHARMA INC.
		
	By:	 	 /s/ David
Wood                    

	Name:	 	David Wood
	Title:	 	Chief Financial Officer
	
	Authorized Signing Officer

  
 - 38 - 

 SCHEDULE “A” 

TERMS AND CONDITIONS FOR UNITED STATES OFFERS AND SALES 

As used in this Schedule “A” and related appendices, capitalized terms used herein and not defined herein shall have the meanings ascribed thereto
in the Agreement to which this Schedule “A” is annexed and the following terms shall have the meanings indicated: 
  

	 	(a)	“Directed Selling Efforts” means directed selling efforts as that term is defined in Rule 902(c) of Regulation S. Without limiting the foregoing, but for greater clarity in this Schedule, it means,
subject to the exclusions from the definition of directed selling efforts contained in Regulation S, any activity undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United States
for the Offered Securities or Shares and includes the placement of any advertisement in a publication with a general circulation in the United States that refers to the offering of the Offered Securities;  

 

	 	(b)	“Distribution Compliance Period” means the 40 day period that begins on the later of (i) the date the Offered Securities are first offered to persons other than distributors in reliance on
Regulation S or (ii) the Closing Date; provided that, all offers and sales by a distributor of an unsold allotment or subscription shall be deemed to be made during the Distribution Compliance Period;  

 

	 	(c)	“Foreign Issuer” means “foreign issuer” as that term is defined in Rule 902(e) of Regulation S; 

  

	 	(d)	“Institutional Accredited Investor” means an entity that is an “accredited investor” as defined in Rule 501(a)(1), (2), (3) or (7) of Regulation D under the U.S. Securities Act;

  

	 	(e)	“Regulation D” means Regulation D adopted by the SEC under the U.S. Securities Act; 

  

	 	(f)	“Substantial U.S. Market Interest” means “substantial U.S. market interest” as that term is defined in Rule 902(j) of Regulation S; and 

 

	 	(g)	“U.S. Placement Memorandum” means the U.S. private placement memorandum (which shall include the Prospectus) used to make offers and sales of the Offered Securities in the United States on a
private placement basis pursuant to section 4(a)(2) or the 1933 Act. 

 Representations, Warranties and Covenants of the Agent

 The Agent acknowledges that the Offered Shares, Warrants and Warrant Shares have not been registered under the 1933 Act and may be offered and
sold only in transactions exempt from or not subject to the registration requirements of the 1933 Act and applicable state securities laws. Accordingly, the Agent represents, warrants and covenants to the Corporation that: 

 

	1.	It has not offered and sold, and will not offer and sell, any Offered Securities except (a) to a person that is not a U.S. Person in an offshore transaction in accordance with Rule 903 of Regulation S or
(b) in the United States or to, or for the account or benefit of, a U.S. Person as provided in Sections 2 through 13 below. Accordingly, neither the Agent nor any of its affiliates nor any persons acting on its behalf, has made or will make
(except as permitted in Sections 2 through 13 below), (i) any offer to sell or any solicitation of an offer to buy, any Offered Securities in the United States or to, or for the account or benefit of, a U.S. Person, (ii) any sale to any
purchaser unless, at the time the buy order was or will have been originated, the purchaser was outside the United States, or the Agent, affiliate or person acting on its behalf reasonably believed that such purchaser was outside the United States,
or (iii) any Directed Selling Efforts in the United States with respect to the Offered Securities. 

	2.	It acknowledges that there is a Substantial U.S. Market Interest in the Common Shares and agrees to comply with Rule 903(b)(2) in connection with the Offering. In particular, it agrees that, at or prior to confirmation
of the sale of the Offered Securities, it will have sent to each distributor, dealer or person receiving a selling concession, fee or other remuneration that purchases Offered Shares or Warrants from it during the Distribution Compliance Period a
confirmation or notice to substantially the following effect: 

 “The securities covered hereby have not been registered
under the U.S. Securities Act of 1933 (the “1933 Act”), and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (i) as part of their distribution at any time or
(ii) otherwise until 40 days after the later of the commencement of the offering and closing date, except in either case in accordance with Regulation S under the 1933 Act. Terms used herein have the meanings given to them in Regulation
S.” 
 In addition, prior to the expiration of the Distribution Compliance Period, all subsequent offers and sales of the Offered
Shares, Warrants, Warrant Shares, Broker Warrants or Broker Shares by the Agent shall be made only in accordance with the provision of Rule 903 or 904 of Regulation S; pursuant to a registration of such securities under the 1933 Act; or pursuant to
an available exemption from the registration requirements of the 1933 Act. The Agent agrees to obtain substantially identical undertakings from the U.S. Agent in connection with the distribution of the Offered Securities contemplated hereby and to
comply with the offering restriction requirements of Rule 903(b)(2) of Regulation S. 
  

	3.	It has not entered and will not enter into any contractual arrangement with respect to the distribution of the Offered Securities, except with the U.S. Agent, any selling group members or with the prior written consent
of the Corporation. It shall require the U.S. Agent and each selling group member to agree, for the benefit of the Corporation, to comply with, and shall use its best efforts to ensure that the U.S. Agent and each selling group member complies with,
the provisions of this Schedule “A” applicable to the Agent as if such provisions applied to the U.S. Agent and such selling group member. 

  

	4.	All offers and sales of Offered Securities in the United States or to, or for the account or benefit of, U.S. Persons shall be made by the Agent through the U.S. Agent, which on the dates of such offers and sales was
and will be duly registered as a broker-dealer under the 1934 Act and under all applicable state securities laws (except where exempted from the respective state’s broker- dealer registration requirements) and a member of, and in good standing
with, the Financial Industry Regulatory Authority, Inc. (“FINRA”), in accordance with all applicable United States state and federal securities (including broker-dealer) laws. The U.S. Agent will make all offers and sales of Offered
Securities in compliance with all applicable United States federal and state broker-dealer requirements. 

  

	5.	It and its affiliates have not, either directly or through a person acting on its or their behalf, solicited and will not solicit offers for, and have not offered to sell and will not offer to sell, any of the Offered
Securities in the United States or to, or for the account or benefit of, U.S. Persons by any form of General Solicitation or General Advertising or in any manner involving a public offering within the meaning of Section 4(a)(2) of the 1933 Act.

  
 A-2 

	6.	Any offer, sale or solicitation of an offer to buy Offered Securities that has been made or will be made in the United States or to, or for the account or benefit of, U.S. Persons was or will be made only to a limited
number of Institutional Accredited Investors with whom the Agent or the U.S. Agent has a pre-existing relationship in transactions that are exempt from registration under the 1933 Act and applicable state
securities laws. 

  

	7.	It had reasonable grounds to believe and did believe that each such purchaser was an Institutional Accredited Investor, and at the time of completion of each sale to a person in the United States or to, or for the
benefit or account of, a U.S. Person, the Agent, the U.S. Agent, their respective affiliates, and any person acting on their behalf will have reasonable grounds to believe and will believe, that each such purchaser designated by the Agent or the
U.S. Agent to purchase Offered Securities from the Corporation is an Institutional Accredited Investor. 

  

	8.	At least one Business Day prior to the Closing Date and the Over-Allotment Option Closing Date, as the case may be, the Corporation will be provided with a list of all purchasers of the Offered Securities that are in
the United States or are U.S. Persons. 

  

	9.	On the Closing Date and the Over-Allotment Option Closing Date, as the case may be, the U.S. Agent and the Agent, will provide a certificate, substantially in the form of Appendix II, relating to the manner of the offer
and sale of the Offered Securities in the United States and to, or for the account or benefit of, U.S. Persons. 

  

	10.	Prior to soliciting any offerees and prior to the completion of any sale of Offered Securities, each purchaser will be informed that the Offered Shares, Warrants and Warrant Shares have not been registered under the
1933 Act and are being offered to such purchaser for investment and in reliance on an exemption from the registration requirements of the 1933 Act provided by Section 4(a)(2) of the 1933 Act. 

 

	11.	Each offeree in the United States shall be provided, prior to time of such offeree’s purchase of any Offered Securities, with a copy of the U.S. Placement Memorandum and no other written material shall be used in
connection with the offer or sale of the Offered Securities in the United States. 

  

	12.	None of the Agent, the U.S. Agent nor any person acting on its or their behalf has engaged or will engage in any violation of Regulation M under the 1934 Act in connection with its offers or sales of the Offered
Securities in the United States. 

  

	13.	It shall cause each U.S. Investor to complete and provide to the Corporation a copy of the U.S. Purchaser’s Letter attached to the U.S. Placement Memorandum. 

Representations, Warranties and Covenants of the Corporation 

The Corporation represents, warrants, covenants and agrees that: 
  

	1.	The Corporation is not, and as a result of the sale of the Offered Securities contemplated hereby will not be, an “investment company” as defined in the United States Investment Company Act of 1940.

  
 A-3 

	2.	The Corporation is a “Foreign Issuer” and reasonably believes there is a Substantial U.S. Market Interest in the Common Shares. 

 

	3.	Except with respect to offers and sales to Institutional Accredited Investors through the Agent or the U.S. Agent in reliance upon an exemption from registration under the 1933 Act, neither the Corporation nor any of
its affiliates, nor any person acting on its or their behalf (other than the Agent, the U.S. Agent, or any members of the banking and selling group formed by them, as to whom the Corporation makes no representation), has made or will make:
(A) any offer to sell, or any solicitation of an offer to buy, any Offered Securities to a person in the United States or to, or for the account or benefit of, U.S. Persons; or (B) any sale of Offered Securities unless, at the time the buy
order was or will have been originated, the purchaser is (i) outside the United States and is not a U.S. Person, or (ii) the Corporation, its affiliates, and any person acting on their behalf reasonably believe that the purchaser is
outside the United States and is not a U.S. Person. 

  

	4.	Neither it nor any of its affiliates, nor any person acting on its or their behalf (other than the Agent, the U.S. Agent, or any members of the banking and selling group formed by them, as to whom the Corporation makes
no representation), has made or will make any Directed Selling Efforts in the United States with respect to the Offered Securities, or has taken or will take any action that would cause the applicable exemption afforded by the 1933 Act or Regulation
S to be unavailable for offers and sales of the Offered Securities pursuant to this Agreement. 

  

	5.	None of the Corporation, any of its affiliates or any person acting on its or their behalf (other than the Agent, its Affiliate, or any members of the banking and selling group formed by them, as to all of whom the
Corporation makes no representation) has offered or will offer to sell, or has solicited or will solicit offers to buy, any of the Offered Securities in the United States or to, or for the account or benefit of, U.S. Persons by means of any form of
General Solicitation or General Advertising or in any manner involving a public offering within the meaning of Section 4(a)(2) of the 1933 Act. 

  

	6.	None of the Corporation, its affiliates or any person acting on its behalf (other than the Agent, the U.S. Agent, or any members of the banking and selling group formed by them, as to all of whom the Corporation makes
no representation) has engaged or will engage in any violation of Regulation M under the 1934 Act in connection with any offer or sale of the Offered Securities. 

  

	7.	Except with respect to the aborted offering of units in July 2017, offers and sales of securities pursuant to the Corporation’s employee benefit plans and the Offering, neither the Corporation nor anyone acting on
its behalf has offered the Offered Securities or any similar securities for sale to, or solicited any offer to buy the same from, a person in the United States or a U.S. Person for a period of six months prior to the date of the Agency Agreement.

  

	8.	Other than the Agent and the U.S. Agent, the Corporation has not dealt with any broker, finder, commission agent, placement agent or arranger in connection with the offer and sale of the Offered Securities and the
transactions contemplated by the Agency Agreement. 

  
 A-4 

 APPENDIX II 

TO SCHEDULE “A” 

AGENT’S CERTIFICATE 
 In connection
with the private placement in the United States of common shares and/or pre-funded common share purchase warrants (the “Offered Securities”) of ESSA Pharma Inc. (the
“Company”), pursuant to a second amended and restated amended and restated agency agreement (the “Agency Agreement”) dated January 5, 2018, between the Corporation and the agent named therein, the undersigned
hereby certify as follows: 
  

	(i)	on the date hereof and on the date of each offer or sale of Offered Securities, H.C. Wainwright & Co. LLC (the “U.S. Agent”) is and was a duly registered broker-dealer with the SEC, duly
registered as a broker-dealer under the laws of each state where it made offers of Offered Securities (unless exempted from the respective state’s broker-dealer registration requirements), and a member of and is in good standing with FINRA on
the date hereof; 

  

	(ii)	all offers and sales of Offered Securities in the United States or to, or for the account or benefit of, U.S. Persons have been and will be effected by the U.S. Agent in accordance with all applicable United States
state and federal broker-dealer requirements; 

  

	(iii)	other than written materials provided by or expressly approved by the Company, no written material was used in connection with the offer and sale of the Offered Securities in the United States or to, or for the account
or benefit of, U.S. Persons; 

  

	(iv)	we have offered the Offered Securities on behalf of the Company to not more than                      offerees that are
in the United States or that are U.S. Persons (including purchasers that have executed and delivered a U.S. Purchaser’s Letter (included as Exhibit 1 to the U.S. Placement Memorandum) and have not made any offer or sale of the Offered
Securities to any other person in the United States or that is a U.S. Person; 

  

	(v)	each offeree in the United States or that is a U.S. Person was provided, prior to time of such offeree’s purchase of any Offered Securities, with a copy of the U.S. Placement Memorandum; 

 

	(vi)	each purchaser of Offered Securities in the United States or that is a U.S. Person has executed and delivered a U.S. Purchaser’s Letter (included as Exhibit 1 to the U.S. Placement Memorandum), a copy of which has
been delivered to the Company; 

  

	(vii)	we had reasonable grounds to believe and did believe that each offeree in the United States or that is a U.S. Person was immediately prior to our transmitting of the U.S. Placement Memorandum to offerees in the United
States, an Institutional Accredited Investor, and, on the date hereof, we continue to believe that each such person in the United States purchasing Offered Securities is an Institutional Accredited Investor; 

 

	(viii)	no form of General Solicitation or General Advertising was used by us in connection with the offer or sale of the Offered Securities in the United States or to, or for the account or benefit of, U.S. Persons; and

  

	(ix)	the offering of the Offered Securities in the United States or to, or for the account or benefit of, U.S. Persons has been conducted by us in accordance with the terms of the Agency Agreement. 

Terms used in this certificate have the meanings given to them in the Agency Agreement unless otherwise defined herein. 

  
 A-5 

 Dated this day      of
            , 201  . 
  

									
	BLOOM BURTON SECURITIES INC.	 		 	H.C. WAINWRIGHT & CO. LLC
					
	By:	 	      
	 		 	By:	 	      

	Name:	 	
                     

	 		 	Name:	 	
                     
    

	Title:	 	      
	 		 	Title:	 	      

  
 A-6 

 SCHEDULE “C” 

PARTIALLY EXCLUDED PURCHASERS 
 Clarus
Lifesciences III, L.P. 
 Members of the Corporation’s Board of Directors (other than David Parkinson and Franklin Berger) 

Management and employees of the Company (other than David Parkinson) 

Omega Fund IV, L.P. 
 Eventide Gilead Fund 

Eventide Healthcare and Life Sciences Fund 

 SCHEDULE “C” 

REGISTERED CORPORATION IP 

(please see attached)Novo
Integrated Sciences, Inc.

2018
Incentive Plan

 

Dated
as of January 16, 2018

 

	1.	Establishment
    and Effective Date. Novo Integrated Sciences, Inc., a Nevada corporation (the “Company”)
    has established this Novo Integrated Sciences, Inc. 2018 Incentive Plan (the “Plan”) as of
    the date first set forth above, which shall be the effective date of the Plan (the “Effective Date”).
	 	 
	2.	Purpose.
    The purpose of this Plan is to aid the Company in attracting, retaining, motivating and rewarding employees, non-employee
    directors and key consultants to the Company or its subsidiaries, to provide for equitable and competitive compensation opportunities,
    to recognize individual contributions and reward achievement of Company goals, and promote the creation of long-term value
    for stockholders by closely aligning the interests of Participants with those of stockholders. The Plan authorizes equity-based
    and cash-based incentives for Participants.
	 	 
	3.	Definitions.
    In addition to the terms defined above and elsewhere in the Plan, the following capitalized terms used in the Plan have
    the respective meanings set forth in this Section:
	 	 
	 	(a)	“Award”
    means any Option, SAR, Restricted Stock, Phantom Stock, Sale Phantom Stock, Stock granted as a bonus, Performance Award, other
    Stock-Based Award or Annual Incentive Award, together with any related right or interest, granted to a Participant under the
    Plan.
	 	 	 
	 	(b)	“Award
    Agreement” means a Stock Option Agreement, a Stock Appreciation Rights Agreement, a Phantom Stock Agreement, a Sale
    Phantom Stock Agreement, a Restricted Stock Agreement, an agreement related to another share-based agreement pursuant to Section
    7(h) or an agreement related to a Performance Award pursuant to Section 7(g) and Section 8, as applicable.
	 	 	 
	 	(c)	“Beneficiary”
    means the legal representatives of the Participant’s estate entitled by will or the laws of descent and distribution
    to receive the benefits under a Participant’s Award upon a Participant’s death, provided that, if and to the extent
    authorized by the Committee, a Participant may be permitted to designate a Beneficiary, in which case the “Beneficiary”
    instead will be the person, persons, trust or trusts (if any are then surviving) which have been designated by the Participant
    in his or her most recent written beneficiary designation filed with the Company to receive the benefits specified under the
    Participant’s Award upon such Participant’s death.
	 	 	 
	 	(d)	“Board”
    means the Company’s Board of Directors.
	 	 	 
	 	(e)	“Change
    in Control” and related terms have the meanings specified in Section 10(c).
	 	 	 
	 	(f)	“Code”
    means the Internal Revenue Code of 1986, as amended, and proposed and final Treasury Department regulations issued thereunder.
	 	 	 
	 	(g)	“Committee”
    means the Compensation Committee of the Board, if one exists, or the Board if a Compensation Committee does not exist at any
    time.
	 	 	 
	 	(h)	“Effective
    Date” has the meaning specified in Section 1.
	 	 	 
	 	(i)	“Eligible
    Person” has the meaning specified in Section 6.
	 	 	 

    	 	1	 

    	 	 	 

    

 

	 	(j)	“Exchange
    Act” means the Securities Exchange Act of 1934, as amended.
	 	 	 
	 	(k)	“Fair
    Market Value” means the fair market value per share of Stock as determined by the Committee under any method of
    determining fair market value as shall be permissible under the Code and the rules and regulations thereunder.
	 	 	 
	 	(l)	“Option”
    means a right, granted to a Participant under Section 7(b), to purchase Stock at a specified price during specified time periods.
	 	 	 
	 	(m)	“Other
    Stock-Based Awards” means Awards granted to a Participant under Section 7(h).
	 	 	 
	 	(n)	“Participant”
    means a person who has been granted an Award under the Plan which remains outstanding, including a person who is no longer
    an Eligible Person.
	 	 	 
	 	(o)	“Performance
    Award” means a conditional right, granted to a Participant under Section 7(g) and Section 8, to receive cash, Stock
    or other Awards or payments, as determined by the Committee, based upon performance criteria specified by the Committee.
	 	 	 
	 	(p)	“Phantom
    Stock” means a right granted to a Participant under Section 7(d).
	 	 	 
	 	(q)	“Restricted
    Stock” means Stock granted to a Participant under Section 7(f) which is subject to certain restrictions and to a
    risk of forfeiture.
	 	 	 
	 	(r)	“Sale
    Phantom Stock” means a right granted to a Participant under Section 7(e).
	 	 	 
	 	(s)	“Stock”
    means the Company’s Common Stock, and any other equity securities of the Company that may be substituted or resubstituted
    for Stock pursuant to Section 12(c).
	 	 	 
	 	(t)	“Stock
    Appreciation Rights” or “SAR” means a right granted to a Participant under Section 7(c).
	 	 	 
	 	(u)	“Termination
    of Service” means (1) with respect to an Award granted to an employee, the termination of the employment relationship
    between the employee and the Company; (2) with respect to an Award granted to a consultant, the termination of the consulting
    or advisory arrangement between the consultant and the Company; and (3) with respect to an Award granted to a non-employee
    director, the cessation of the provision of services as a director of the Company. A Termination of Service shall not be deemed
    to have resulted by reason of a bona fide leave of absence approved by the Company. Notwithstanding the foregoing, if the
    Participant’s status changes from employee, consultant or non-employee director to any other status eligible to receive
    an Award under the Plan, no Termination of Service shall occur for purposes of the Plan until the Participant’s new
    status with the Company terminates.

 

	4.	Administration.

 

	 	(a)	Authority
    of the Committee. The Plan shall be administered by the Committee, which shall have full and final authority, in each
    case subject to and consistent with the provisions of the Plan, to select Eligible Persons to become Participants; to grant
    Awards; to determine the type and number of Awards, the dates on which Awards may be exercised and on which the risk of forfeiture
    or deferral period relating to Awards shall lapse or terminate, the acceleration of any such dates, the expiration date of
    any Award, whether, to what extent, and under what circumstances an Award may be settled, or the exercise price of an Award
    may be paid, in cash, Stock, other Awards, or other property, and other terms and conditions of, and all other matters relating
    to Awards; to prescribe documents evidencing or setting terms of Awards (such Award documents need not be identical for each
    Participant), amendments thereto, and rules and regulations for the administration of the Plan and amendments thereto; to
    construe and interpret the Plan and Award documents and correct defects, supply omissions or reconcile inconsistencies therein;
    and to make all other decisions and determinations as the Committee may deem necessary or advisable for the administration
    of the Plan. Decisions of the Committee with respect to the administration and interpretation of the Plan shall be final,
    conclusive, and binding upon all persons interested in the Plan, including Participants, Beneficiaries, transferees under
    Section 12(b) and other persons claiming rights from or through a Participant, and stockholders.
	 	 	 

    	 	2	 

    	 	 	 

    

 

	 	(b)	Limitation
    of Liability. The Committee and each member thereof, and any person acting pursuant to authority delegated by the Committee,
    shall be entitled, in good faith, to rely or act upon any report or other information furnished by any executive officer,
    other officer or employee of the Company or a subsidiary, the Company’s independent auditors, consultants, legal counsel
    or any other agents assisting in the administration of the Plan. Members of the Committee, any person acting pursuant to authority
    delegated by the Committee, and any officer or employee of the Company or a subsidiary acting at the direction or on behalf
    of the Committee or a delegee shall not be personally liable for any action or determination taken or made in good faith with
    respect to the Plan, and shall, to the extent permitted by law, be fully indemnified and protected by the Company with respect
    to any such action or determination.

 

	5.	Stock
    Subject to Plan.

 

	 	(a)	Overall
    Number of Shares Available for Delivery. Subject to adjustment as provided in Section 12(c), the total number of shares
    of Stock reserved and available for delivery in connection with Awards under the Plan (excluding, for the avoidance of doubt,
    any Phantom Stock or Sale Phantom Stock) shall be 10,000,000 shares of common stock of the Company. Any shares of Stock delivered
    under the Plan shall consist of authorized and unissued shares or treasury shares.
	 	 	 
	 	(b)	Share
    Counting Rules.
	 	 	 
	 	 	(i)	The
    Committee may adopt reasonable counting procedures to ensure appropriate counting, avoid double counting (as, for example,
    in the case of tandem or substitute awards) and make adjustments if the number of shares of Stock actually delivered differs
    from the number of shares previously counted in connection with an Award.
	 	 	 	 
	 	 	(ii)	Shares
    that are potentially deliverable under an Award under the Plan that are canceled, expired, forfeited, settled in cash or otherwise
    terminated without a delivery of such shares to the Participant will not be counted as delivered under the Plan and shall
    be available for Awards under this Plan. However, shares withheld in payment of the exercise price or taxes relating to an
    Award and shares equal to the number surrendered in payment of any exercise price or taxes relating to an Award shall be deemed
    to constitute shares delivered to the Participant and shall not be available for reissue as Awards under this Plan.
	 	 	 	 
	 	 	(iii)	Because
    shares will count against the number reserved in Section 5(a) upon delivery, and subject to the share counting rules under
    this Section 5(b), the Committee may determine that Awards may be outstanding that relate to a greater number of shares than
    the aggregate remaining available under the Plan, so long as Awards will not result in delivery and vesting of shares in excess
    of the number then available under the Plan.
	 	 	 	 

    	 	3	 

    	 	 	 

    

 

	6.	Eligibility.
    Awards may be granted under the Plan only to Eligible Persons. For purposes of the Plan, an “Eligible Person”
    means an employee of the Company or any subsidiary, a non-employee director or key consultant to the Company, or a subsidiary,
    and any person who has been offered employment by the Company or a subsidiary, provided that such prospective employee may
    not receive any payment or exercise any right relating to an Award until such person has commenced employment with the Company
    or a subsidiary.
	 	 
	7.	Specific
    Terms of Awards.

 

	 	(a)	General.
    Awards may be granted on the terms and conditions set forth in this Section 7. In addition, the Committee may impose on
    any Award or the exercise thereof, at the date of grant or thereafter (subject to Section 12(e)), such additional terms and
    conditions, not inconsistent with the provisions of the Plan, as the Committee shall determine, including terms requiring
    forfeiture of Awards in the event of Termination of Service by the Participant, terms in the event of a Change in Control
    and terms permitting a Participant to make elections relating to his or her Award. The Committee shall retain full power and
    discretion with respect to any term or condition of an Award that is not mandatory under the Plan. The Committee shall require
    the payment of lawful consideration for an Award to the extent necessary to satisfy the requirements of the Nevada Revised
    Statutes, and may otherwise require payment of consideration for an Award except as limited by the Plan.
	 	 	 
	 	(b)	Options.
    The Committee is authorized to grant Options to Participants on the following terms and conditions which options may be
    incentive options or non-qualified options for purposes of the Code:
	 	 	 
	 	 	(i)	The
    exercise price per share of Stock purchasable under an Option shall be determined by the Committee, provided that such exercise
    price shall be not less than the Fair Market Value of a share of Stock on the date of grant of such Option.
	 	 	 	 
	 	 	(ii)	The
    Committee shall determine the term of each Option, provided that in no event shall the term of any Option or SAR issued in
    tandem therewith exceed seven years. The Committee shall determine the time or times at which or the circumstances under which
    an Option may be exercised in whole or in part (including based on achievement of performance goals and future service requirements),
    the methods by which such exercise price may be paid or deemed to be paid and the form of such payment (subject to Section
    12(j)), including, without limitation, cash, Stock (including through withholding of Stock deliverable upon exercise, if such
    withholding will not result in the recognition of additional accounting expense to the Company), other Awards or awards granted
    under other plans of the Company or any subsidiary, or other property (including through “cashless exercise” arrangements,
    to the extent permitted by applicable law), and the methods by or forms in which Stock will be delivered or deemed to be delivered
    in satisfaction of Options to Participants.
	 	 	 	 
	 	 	(iii)	Options
    shall be issued pursuant to a Stock Option Agreement, substantially in the form as attached hereto as Exhibit A.
	 	 	 	 
	 	(c)	Stock
    Appreciation Rights. The Committee is authorized to grant SARs to Participants on the following terms and conditions:
	 	 	 
	 	 	(i)	An
    SAR shall confer on the Participant to whom it is granted a right to receive, upon vesting thereof, an amount in case equal
    to the excess of (A) the Fair Market Value of one share of Stock on the date of exercise (or, in the case of a “Limited
    SAR,” the Fair Market Value determined by reference to the Change in Control Price, as defined under Section 10(d))
    over (B) the grant price of the SAR as determined by the Committee.
	 	 	 	 

    	 	4	 

    	 	 	 

    

 

 

	 	 	(ii)	The
    Committee shall determine at the date of grant or thereafter, the time or times at which and the circumstances under which
    a SAR may be exercised in whole or in part (including based on achievement of performance goals and future service requirements),
    the method of exercise, method of settlement, form of consideration payable in settlement, method by or forms in which Stock
    will be delivered or deemed to be delivered to Participants, whether or not a SAR shall be free-standing or in tandem or combination
    with an Option, and the maximum term of a SAR, which in no event shall exceed a period of seven years from the date of grant.
    Limited SARs that may only be exercised in connection with a Change in Control or other event as specified by the Committee
    may be granted on such terms, not inconsistent with this Section 7(c), as the Committee may determine.
	 	 	 	 
	 	 	(iii)	Stock
    Appreciation Rights shall be granted pursuant to a Stock Appreciation Rights Agreement, substantially in the form as attached
    hereto as Exhibit B.
	 	 	 	 
	 	(d)	Phantom
    Stock. The Committee is authorized to grant Phantom Stock to Participants on the following terms and conditions:
	 	 	 
	 	 	(i)	A
    share of Phantom Stock shall confer on the Participant to whom it is granted a right to receive, upon vesting thereof, such
    payments or amounts as set forth in the Phantom Stock Agreement.
	 	 	 	 
	 	 	(ii)	The
    Committee shall determine at the date of grant or thereafter, the time or times at which and the circumstances under which
    Phantom Stock shall vest in whole or in part, method of settlement, form of consideration payable in settlement.
	 	 	 	 
	 	 	(iii)	Phantom
    Stock shall be issued pursuant to a Phantom Stock Agreement, substantially in the form as attached hereto as Exhibit C-1.
    Shares of Phantom Stock shall not be certificated.
	 	 	 	 
	 	(e)	Sale
    Phantom Stock. The Committee is authorized to grant Sale Phantom Stock to Participants on the following terms and conditions:
	 	 	 
	 	 	(i)	A
    share of Phantom Stock shall confer on the Participant to whom it is granted a right to receive a proportionate share of such
    payments or amounts as set forth in the Sale Phantom Stock Agreement.
	 	 	 	 
	 	 	(ii)	The
    Committee shall determine at the date of grant or thereafter, method of settlement, and form of consideration payable in settlement
    as to any Sale Phantom Stock.
	 	 	 	 
	 	 	(iii)	Sale
    Phantom Stock shall be issued pursuant to a Sale Phantom Stock Agreement, substantially in the form as attached hereto as
    Exhibit C-2. Shares of Sale Phantom Stock shall not be certificated.
	 	 	 	 
	 	(f)	Restricted
    Stock. The Committee is authorized to grant Restricted Stock to Participants on the following terms and conditions:
	 	 	 
	 	 	(i)	Restricted
    Stock shall be subject to such restrictions on transferability, risk of forfeiture and other restrictions, if any, as the
    Committee may impose, which restrictions may lapse separately or in combination at such times, under such circumstances (including
    based on achievement of performance goals and future service requirements), in such installments or otherwise and under such
    other circumstances as the Committee may determine at the date of grant or thereafter. Except to the extent restricted under
    the terms of the Plan and any Award document relating to the Restricted Stock, a Participant granted Restricted Stock shall
    have all of the rights of a stockholder, including the right to vote the Restricted Stock and the right to receive dividends
    thereon (subject to any mandatory reinvestment or other requirement imposed by the Committee).
	 	 	 	 

    	 	5	 

    	 	 	 

    

 

	 	 	(ii)	Except
    as otherwise determined by the Committee, upon Termination of Service during the applicable restriction period, Restricted
    Stock that is at that time subject to restrictions shall be forfeited and reacquired by the Company; provided that the Committee
    may provide, by rule or regulation or in any Award document, or may determine in any individual case, that restrictions or
    forfeiture conditions relating to Restricted Stock will lapse in whole or in part, including in the event of terminations
    resulting from specified causes.
	 	 	 	 
	 	 	(iii)	Restricted
    Stock granted under the Plan may be evidenced in such manner as the Committee shall determine. If certificates representing
    Restricted Stock are registered in the name of the Participant, the Committee may require that such certificates bear an appropriate
    legend referring to the terms, conditions and restrictions applicable to such Restricted Stock, that the Company retain physical
    possession of the certificates, and that the Participant deliver a stock power to the Company, endorsed in blank, relating
    to the Restricted Stock.
	 	 	 	 
	 	 	(iv)	Restricted
    Stock shall be issued pursuant to a Restricted Stock Agreement, substantially in the form as attached hereto as Exhibit D.
	 	 	 	 
	 	(g)	Performance
    Awards. Performance Awards, denominated in cash or in Stock or other Awards, may be granted by the Committee in accordance
    with Section 8.
	 	 	 
	 	(h)	Other
    Stock-Based Awards. The Committee is authorized, subject to limitations under applicable law, to grant to Participants
    such other Awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on,
    or related to, Stock or factors that may influence the value of Stock, including, without limitation, convertible or exchangeable
    debt securities, other rights convertible or exchangeable into Stock, purchase rights for Stock, Awards with value and payment
    contingent upon performance of the Company or business units thereof or any other
    factors designated by the Committee, and Awards valued by reference to the book value of Stock or the value of securities
    of or the performance of specified subsidiaries or other business units. The Committee shall determine the terms and conditions
    of such Awards. Stock delivered pursuant to an Award in the nature of a purchase right granted under this Section 7(h) shall
    be purchased for such consideration, paid for at such times, by such methods, and in such forms, including, without limitation,
    cash, Stock, other Awards, notes, or other property, as the Committee shall determine. Cash awards, as an element of or supplement
    to any other Award under the Plan, may also be granted pursuant to this Section 7(h).

 

	8.	Performance
    Awards.

 

	 	(a)	Performance
    Awards Generally. The Committee is authorized to grant any of the awards described in Sections 7(d), 7(e), 7(f), 7(g)
    and 7(h) as Performance Awards, the terms and conditions of which are described in this Section 8. Performance Awards may
    be denominated as a cash amount, number of shares of Stock, or specified number of other Awards (or a combination) which may
    be earned upon achievement or satisfaction of performance conditions specified by the Committee. In addition, the Committee
    may specify that any other Award shall constitute a Performance Award by conditioning the right of a Participant to exercise
    the Award or have it settled, and the timing thereof, upon achievement or satisfaction of such performance conditions as may
    be specified by the Committee. The Committee may use such business criteria and other measures of performance as it may deem
    appropriate in establishing any performance conditions, and may exercise its discretion to reduce or increase the amounts
    payable under any Award subject to performance conditions.

 

    	 	6	 

    	 	 	 

    

 

	 	(b)	Performance
    Goal Generally. The performance goal for such Performance Awards shall consist of one or more business criteria and a
    targeted level or levels of performance with respect to each of such criteria, as specified by the Committee consistent with
    this Section 8. The performance goal shall be objective, including the requirement that the level or levels of performance
    targeted by the Committee result in the achievement of performance goals being “substantially uncertain.” The
    Committee may determine that such Performance Awards shall be granted, exercised and settled upon achievement of any one performance
    goal or that two or more of the performance goals must be achieved as a condition to grant, exercise and settlement of such
    Performance Awards. Performance goals may differ for Performance Awards granted to any one Participant or to different Participants.

 

	 	 	(i)	One
    or more of the following business criteria for the Company, on a consolidated basis, shall be used by the Committee in establishing
    performance goals for such Performance Awards: (1) revenues;
    (2) earnings from operations, earnings before or after taxes, earnings before or after interest, depreciation, amortization,
    incentives, service fees or extraordinary or special items; (3) net income or net income per common share (basic or
    diluted);     (4) return on assets, return on net assets, return on investment, return on capital, or return on equity; (5)
    cash flow, free     cash flow, cash flow return on investment, or net cash provided by operations; (6) economic value created
    or added; (7) operating     margin or profit margin; (8) stock price, dividends or total stockholder return; and (9)
    strategic business criteria, consisting     of one or more objectives based on meeting specified market penetration or value
    added, product development or introduction,     geographic business expansion goals, cost targets, debt reduction, customer
    satisfaction, employee satisfaction, information     technology, and goals relating to acquisitions or divestitures of
    subsidiaries, affiliates or joint ventures. The targeted     level or levels of performance with respect to such business
    criteria may be established at such levels and in such terms     as the Committee may determine, in its discretion, including
    in absolute terms, as a goal relative to performance in prior     periods, or as a goal compared to the performance of one or
    more comparable companies or an index covering multiple companies.
	 	 	 	 
	 	 	(ii)	Achievement
    of performance goals in respect of such Performance Awards shall be measured over a performance period as specified by the
    Committee.
	 	 	 	 
	 	 	(iii)	The
    Committee may establish a Performance Award pool, which shall be an unfunded pool, for purposes of measuring performance of
    the Company in connection with Performance Awards. The amount of such Performance Award pool shall be based upon the achievement
    of a performance goal or goals based on one or more of the business criteria set forth in Section 8(b)(i) during the given
    performance period, as specified by the Committee in accordance with Section 8(b)(ii). The Committee may specify the amount
    of the Performance Award pool as a percentage of any of such business criteria, a percentage thereof in excess of a threshold
    amount, or as another amount which need not bear a strictly mathematical relationship to such business criteria.
	 	 	 	 
	 	 	(iv)	Settlement
    of such Performance Awards shall be in cash, Stock, or other property, in the discretion of the Committee.
	 	 	 	 

    	 	7	 

    	 	 	 

    

 

	9.	Certain
    Provisions Applicable to Awards.

 

	 	(a)	Stand-Alone,
    Additional, Tandem, and Substitute Awards. Options and SARs granted under the Plan may, in the discretion of the Committee,
    be granted either alone or in addition to or in tandem with the other, and any Award granted under the Plan may, in the discretion
    of the Committee, be granted in substitution or exchange for any other Award or any award granted under another plan of the
    Company, or any business entity to be acquired by the Company or a subsidiary, or any other right of a Participant to receive
    payment from the Company or any subsidiary, provided that such substitution or exchange does not cause the recipient to become
    subject to excise taxes under Code Section 409A. Options and SARs granted in addition to or in tandem with the other may be
    granted either as of the same time as or a different time from the grant of such other Award, except to the extent that grants
    at different times would cause the recipient of the Option or SAR to become subject to excise taxes under Code Section 409A.
	 	 	 
	 	(b)	Term
    of Awards. The term of each Award shall be for such period as may be determined by the Committee, subject to the express
    limitations set forth in Section 7(b)(ii).
	 	 	 
	 	(c)	Form
    and Timing of Payment under Awards; Deferrals. Subject to the terms of the Plan (including Section 12(j)) and any applicable
    Award document, payments to be made by the Company or a subsidiary upon the exercise of an Option or other Award or settlement
    of an Award may be made in such forms as the Committee shall determine, including, without limitation, cash, Stock, or other
    property. The settlement of any Award may be accelerated, and cash paid in lieu of Stock in connection with such settlement,
    in the discretion of the Committee or upon occurrence of one or more specified events (subject to Section 12(j)), provided
    such acceleration does not cause the recipient to become subject to excise taxes under Code Section 409A.
	 	 	 
	 	(d)	Limitation
    on Vesting of Certain Awards. If the granting or vesting of full-value Awards (as defined in Section 5(a)) is subject
    to performance conditions, the minimum vesting period of such Awards shall be no less than one year. If neither the granting
    nor vesting of full-value Awards is subject to performance conditions, such Awards shall have a minimum vesting period of
    no less than three years; provided, however, that such Awards may vest on an accelerated basis in the event of a Participant’s
    death, disability, Termination of Service after age 65 (or such other age as determined by the Committee), or in the event
    of a Change in Control or other special circumstances; provided however, the vesting of no more than 10% of the shares of
    Stock authorized under the Plan may be accelerated for other special circumstances. For purposes of this Section 9(d)), (i)
    a performance period that precedes the grant of the Award will be treated as part of the vesting period if the participant
    has been notified promptly after the commencement of the performance period that he or she has the opportunity to earn the
    Award based on performance and continued service, and (ii) vesting over a one-year period or three-year period will include
    periodic vesting (i.e., monthly step vesting in the case of a one-year award, or annual step vesting over a two or three year
    award) over such period if the rate of such vesting is proportional (or less rapid) to the number of months or years that
    have lapsed, as applicable, in such period. The foregoing notwithstanding, up to 10% of the shares of Stock authorized under
    the Plan may be granted as full- value Awards without the minimum vesting requirements set forth in this Section 9(d)).
	 	 	 
	 	(e)	Deferred
    Compensation Awards. Notwithstanding anything to the contrary contained herein, any Award which is subject to Code Section
    409A shall, at a minimum, comply with all of the requirements set forth in Code Section 409A as are necessary to allow the
    deferral of federal income tax on the deferred compensation resulting from the Award and to avoid the constructive receipt
    of such deferred compensation.
	 	 	 

    	 	8	 

    	 	 	 

    

 

	10.	Change
    in Control.

 

	 	(a)	Effect
    of “Change in Control” on Non-Performance Based Awards. In the event of a “Change in Control,”
    the following provisions shall apply to non-performance based Awards, including Awards as to which performance conditions
    previously have been satisfied or are deemed satisfied under Section 10(b), unless otherwise determined by the Committee at
    the time of the Change in Control or as otherwise provided in a current employment agreement between the Company and the Participant
    or as otherwise provided in the applicable Award Agreement:

 

	 	 	(i)	All
    deferral of settlement, forfeiture conditions and other restrictions applicable to Awards granted under the Plan shall lapse
    and such Awards shall be fully payable as of the time of the Change in Control without regard to deferral and vesting conditions,
    except to the extent of any waiver by the Participant or other express election to defer beyond the Change in Control and
    subject to applicable restrictions set forth in Section 12(a);
	 	 	 	 
	 	 	(ii)	Any
    Award carrying a right to exercise that was not previously exercisable and vested shall become fully exercisable and vested
    as of the time of the Change in Control and shall remain exercisable and vested for the balance of the stated term of such
    Award without regard to any Termination of Service by the Participant other than a termination for “cause” (as
    defined in any employment or severance agreement between the Company or its subsidiary and the Participant then in effect
    or, if none, as defined by the Committee and in effect at the time of the Change in Control), subject only to applicable restrictions
    set forth in Section 12(a); and
	 	 	 	 
	 	 	(iii)	The
    Committee may, in its discretion, determine to extend to any Participant who holds an Option the right to elect, during the
    60-day period immediately following the Change in Control, in lieu of acquiring the shares of Stock covered by such Option,
    to receive in cash the excess of the Change in Control Price over the exercise price of such Option, multiplied by the number
    of shares of Stock covered by such Option, and to extend to any Participant who holds other types of Awards denominated in
    shares the right to elect, during the 60-day period immediately following the Change in Control, in lieu of receiving the
    shares of Stock covered by such Award, to receive in cash the Change in Control Price multiplied by the number of shares of
    Stock covered by such Award.

 

	 	(b)	Effect
    of “Change in Control” on Performance-Based Awards. In the event of a “Change in Control,” with
    respect to an outstanding Award subject to achievement of performance goals and conditions, such performance goals and conditions
    shall be deemed to be met or exceeded if and to the extent so provided by the Committee in the Award document governing such
    Award or other agreement with the Participant.
	 	 	 
	 	(c)	Definition
    of “Change in Control.” A “Change in Control” shall be deemed to have occurred if, after the Effective
    Date, there shall have occurred any of the following:

 

	 	 	(i)	a
    complete dissolution or liquidation of the Company, or similar occurrence;
	 	 	 	 
	 	 	(ii)	the
    consummation of a merger, consolidation, acquisition, separation, reorganization, or similar occurrence, where the Company
    is not the surviving entity in a single transaction or a series of related transactions;
	 	 	 	 
	 	 	(iii)	a
    transfer of substantially all of the assets of the Company or more than 50% of the outstanding Common Stock, each in a single
    transaction or a series of related transactions; or

 

    	 	9	 

    	 	 	 

    

 

	 	 	(iv)	the
    individuals who constitute the Board as of the Effective Date, or who have been recommended for election to the Board by two-thirds
    of the Board consisting of individuals who are either on the Board as of the Effective Date or such successors, cease for
    any reason to constitute at least a majority of such Board.

 

Notwithstanding
the foregoing, with respect to any deferred compensation Award which is subject to Code Section 409A and with respect to which
Section 409A(a)(2)(A)(v) is applicable, a “Change in Control” shall not have been deemed to have occurred unless the
requirements of Section 409A(a)(2)(A)(v) have been satisfied.

 

	 	(d)	Definition
    of “Change in Control Price.” “Change in Control Price” means an amount in cash equal to the amount
    of cash and fair market value of property that is the highest price per share paid (including extraordinary dividends) in
    any transaction triggering the Change in Control or any liquidation of shares following a sale of substantially all assets
    of the Company.

 

	11.	Additional
    Award Forfeiture Provisions.

 

	 	(a)	Forfeiture
    of Options and Other Awards and Gains Realized Upon Prior Option Exercises or Award Settlements. Unless otherwise determined
    by the Committee, each Award granted hereunder shall be subject to the following additional forfeiture conditions, to which
    the Participant, by accepting an Award hereunder, agrees. If any of the events specified in Section 11(b)(i), Section 11(b)(ii),
    or Section 11(b)(iii) occurs (a “Forfeiture Event”), all of the following forfeitures will result, with such forfeitures
    becoming effective at the later of the occurrence of the Forfeiture Event or the Participant’s Termination of Service:

 

	 	 	(i)	The
    unexercised portion of the Option, whether or not vested, and any other Award not then settled (except for an Award that has
    not been settled solely due to an elective deferral by the Participant and otherwise is not forfeitable in the event of any
    termination of service of the Participant) will be immediately forfeited and canceled upon the occurrence of the Forfeiture
    Event; and
	 	 	 	 
	 	 	(ii)	The
    Participant will be obligated to repay to the Company, in cash, within five business days after demand is made therefor by
    the Company, the total amount of Award Gain (as defined herein) realized by the Participant upon each exercise of an Option
    or settlement of an Award (regardless of any elective deferral) that occurred on or after (A) the date that is six months
    prior to the occurrence of the Forfeiture Event, if the Forfeiture Event occurred while the Participant was employed by the
    Company or a subsidiary, or (B) the date that is six months prior to the date the Participant’s employment by the Company
    or a subsidiary terminated, if the Forfeiture Event occurred after the Participant ceased to be so employed. For purposes
    of this Section, the term “Award Gain” shall mean (i) in respect of a given Option exercise, the product of (X)
    the Fair Market Value per share of Stock at the date of such exercise (without regard to any subsequent change in the market
    price of shares) minus the exercise price times (Y) the number of shares as to which the Option was exercised at that date,
    and (ii) in respect of any other settlement of an Award granted to the Participant, the Fair Market Value of the cash or Stock
    paid or payable to Participant (regardless of any elective deferral) less any cash or the Fair Market Value of any Stock or
    property (other than an Award or award which would have itself then been forfeitable hereunder and excluding any payment of
    tax withholding) paid by the Participant to the Company as a condition of or in connection with such settlement.

 

    	 	10	 

    	 	 	 

    

 

	 	(b)	Events
    Triggering Forfeiture. The forfeitures specified in Section 11(a) will be triggered upon the occurrence of any one of
    the following Forfeiture Events at any time during the Participant’s employment by the Company or a subsidiary or during
    the one-year period following termination of such employment:

 

	 	 	(i)	The
    Participant, acting alone or with others, directly or indirectly, prior to a Change in Control, (A) engages, either as employee,
    employer, consultant, advisor, or director, or as an owner, investor, partner, or stockholder unless the Participant’s
    interest is insubstantial, in any business in an area or region in which the Company conducts business at the date the event
    occurs, which is directly in competition with a business then conducted by the Company or a subsidiary; (B) induces any customer,
    supplier, licensee or licensor of the Company or a subsidiary, or other company with which the Company or a subsidiary has
    a business relationship, to curtail, cancel, not renew, or not continue his or her or its business with the Company or any
    subsidiary; or (C) induces, or attempts to influence, any employee of or service provider (including, but not limited to,
    licensees and licensors) to the Company or a subsidiary to terminate such employment or service. The Committee shall, in its
    discretion, determine which lines of business the Company conducts on any particular date and which third parties may reasonably
    be deemed to be in competition with the Company. For purposes of this Section 11(b)(i), a Participant’s interest as
    a stockholder is insubstantial if it represents beneficial ownership of less than five percent of the outstanding class of
    stock, and a Participant’s interest as an owner, investor, or partner is insubstantial if it represents ownership, as
    determined by the Committee in its discretion, of less than five percent of the outstanding equity of the entity;
	 	 	 	 
	 	 	(ii)	The
    Participant discloses, uses, sells, or otherwise transfers, except in the course of employment with or other service to the
    Company or any subsidiary, any confidential or proprietary information of the Company or any subsidiary, including but not
    limited to information regarding the Company’s current and potential customers, organization, employees, finances, and
    methods of operations and investments, so long as such information has not otherwise been disclosed to the public or is not
    otherwise in the public domain, except as required by law or pursuant to legal process, or the Participant makes statements
    or representations, or otherwise communicates, directly or indirectly, in writing, orally, or otherwise, or takes any other
    action which may, directly or indirectly, disparage or be damaging to the Company or any of its subsidiaries or their respective
    officers, directors, employees, advisors, businesses or reputations, except as required by law or pursuant to legal process;
    or
	 	 	 	 
	 	 	(iii)	The
    Participant fails to cooperate with the Company or any subsidiary or by making himself or herself available to testify on
    behalf of the Company or such subsidiary in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative,
    or otherwise fails to assist the Company or any subsidiary in any such action, suit, or proceeding by providing information
    and meeting and consulting with members of management of, other representatives of, or counsel to, the Company or such subsidiary,
    as reasonably requested.

 

	 	(c)	Agreement
    Does Not Prohibit Competition or Other Participant Activities. Although the conditions set forth in this Section 11 shall
    be deemed to be incorporated into an Award, a Participant is not thereby prohibited from engaging in any activity, including
    but not limited to competition with the Company and its subsidiaries. Rather, the non-occurrence of the Forfeiture Events
    set forth in Section 11(b) is a condition to the Participant’s right to realize and retain value from his or her compensatory
    Options and Awards, and the consequence under the Plan if the Participant engages in an activity giving rise to any such Forfeiture
    Event are the forfeitures specified herein. The Company and the Participant shall not be precluded by this provision or otherwise
    from entering into other agreements concerning the subject matter of Section 11(a) and
    Section 11(b).

 

    	 	11	 

    	 	 	 

    

 

	 	(d)	Committee
    Discretion. The Committee may, in its discretion, waive in whole or in part the Company’s right to forfeiture under
    this Section, but no such waiver shall be effective unless evidenced by a writing signed by a duly authorized officer of the
    Company. In addition, the Committee may impose additional conditions on Awards, by inclusion of appropriate provisions in
    the document evidencing or governing any such Award.

 

	12.	General
    Provisions.

 

	 	(a)	Compliance
    with Legal and Other Requirements. The Company may, to the extent deemed necessary or advisable by the Committee, postpone
    the issuance or delivery of Stock or payment of other benefits under any Award until completion of such registration or qualification
    of such Stock or other required action under any federal or state law, rule or regulation, listing or other required action
    with respect to any stock exchange or automated quotation system upon which the Stock or other securities of the Company are
    listed or quoted, or compliance with any other obligation of the Company, as the Committee may consider appropriate, and may
    require any Participant to make such representations, furnish such information and comply with or be subject to such other
    conditions as it may consider appropriate in connection with the issuance or delivery of Stock or payment of other benefits
    in compliance with applicable laws, rules, and regulations, listing requirements, or other obligations.
	 	 	 
	 	(b)	Limits
    on Transferability; Beneficiaries. No Award or other right or interest of a Participant under the Plan shall be pledged,
    hypothecated or otherwise encumbered or subject to any lien, obligation or liability of such Participant to any party (other
    than the Company or a subsidiary thereof), or assigned or transferred by such Participant otherwise than by will or the laws
    of descent and distribution or to a Beneficiary upon the death of a Participant, and such Awards or rights that may be exercisable
    shall be exercised during the lifetime of the Participant only by the Participant or his or her guardian or legal representative,
    except that Awards and other rights may be transferred to one or more transferees during the lifetime of the Participant,
    and may be exercised by such transferees in accordance with the terms of such Award, but only if and to the extent such transfers
    are permitted by the Committee, subject to any terms and conditions which the Committee may impose thereon (including limitations
    the Committee may deem appropriate in order that offers and sales under the Plan will meet applicable requirements of registration
    forms under the Securities Act of 1933 specified by the Securities and Exchange Commission). A Beneficiary, transferee, or
    other person claiming any rights under the Plan from or through any Participant shall be subject to all terms and conditions
    of the Plan and any Award document applicable to such Participant, except as otherwise determined by the Committee, and to
    any additional terms and conditions deemed necessary or appropriate by the Committee.
	 	 	 
	 	(c)	Adjustments.
    In the event of any large, special and non-recurring dividend or other distribution (whether in the form of cash or property
    other than Stock), recapitalization, forward or reverse split, Stock dividend, reorganization, merger, consolidation, spin-off,
    combination, repurchase, share exchange, liquidation, dissolution or other similar corporate transaction or event affects
    the Stock, the Committee shall adjust any or all of (i) the number and kind of shares of Stock which may be delivered in connection
    with Awards granted thereafter, (ii) the number and kind of shares of Stock by which annual per-person Award limitations are
    measured under Section 8, (iii) the number and kind of shares of Stock subject to or deliverable in respect of outstanding
    Awards and (iv) the exercise price, grant price or purchase price relating to any Award or, if deemed appropriate, the Committee
    may make provision for a payment of cash or property to the holder of an outstanding Option (subject to Section 12(j)). In
    addition, the Committee is authorized to make adjustments in the terms and conditions of, and the criteria included in, Awards
    (including Performance Awards and performance goals and any hypothetical funding pool relating thereto) in recognition of
    unusual or nonrecurring events (including, without limitation, events described in the preceding sentence, as well as acquisitions
    and dispositions of businesses and assets) affecting the Company, any subsidiary or other business unit, or the financial
    statements of the Company or any subsidiary, or in response to changes in applicable laws, regulations, accounting principles,
    tax rates and regulations or business conditions or in view of the Committee’s assessment of the business strategy of
    the Company, any subsidiary or business unit thereof, performance of comparable organizations, economic and business conditions,
    personal performance of a Participant, and any other circumstances deemed relevant.

 

    	 	12	 

    	 	 	 

    

 

	 	(d)	Tax
    Provisions.

 

	 	 	(i)	The
    Company and any subsidiary is authorized to withhold from any Award granted, any payment relating to an Award under the Plan,
    including from a distribution of Stock, or any payroll or other payment to a Participant, amounts of withholding and other
    taxes due or potentially payable in connection with any transaction involving an Award, and to take such other action as the
    Committee may deem advisable to enable the Company and Participants to satisfy obligations for the payment of withholding
    taxes and other tax obligations relating to any Award. This authority shall include authority to withhold or receive Stock
    or other property and to make cash payments in respect thereof in satisfaction of a Participant’s withholding obligations,
    either on a mandatory or elective basis in the discretion of the Committee. Other provisions of the Plan notwithstanding,
    only the minimum amount of Stock deliverable in connection with an Award necessary to satisfy statutory withholding requirements
    will be withheld, except a greater amount of Stock may be withheld if such withholding would not result in the recognition
    of additional accounting expense to the Company.
	 	 	 	 
	 	 	(ii)	No
    election under Code Section 83(b) (to include in gross income in the year of transfer the amounts specified in Code Section
    83(b)) or under a similar provision of the laws of a jurisdiction outside the United States may be made unless expressly permitted
    by the terms of the Award document or by action of the Committee in writing prior to the making of such election, which election
    right shall not be unreasonably withheld if the Participant requests to make such an election in writing to the Committee.
    In any case in which a Participant is permitted to make such an election in connection with an Award, the Participant shall
    notify the Company of such election within ten days of filing notice of the election with the Internal Revenue Service or
    other governmental authority, in addition to any filing and notification required pursuant to regulations issued under Code
    Section 83(b) or other applicable provision.

 

	 	(e)	Changes
    to the Plan. The Board may amend, suspend or terminate the Plan or the Committee’s authority to grant Awards under
    the Plan without the consent of stockholders or Participants; provided, however, that any amendment to the Plan shall be submitted
    to the Company’s stockholders for approval not later than the earliest annual meeting for which the record date is after
    the date of such Board action if such stockholder approval is required by any federal or state law or regulation or the rules
    of any stock exchange or automated quotation system on which the Stock may then be listed or quoted, and the Board may otherwise,
    in its discretion, determine to submit other amendments to the Plan to stockholders for approval and provided further, that,
    without the consent of an affected Participant, no such Board action may materially and adversely affect the rights of such
    Participant under any outstanding Award. Except in connection with a corporate transaction involving the Company (including,
    without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger,
    consolidation, split-up, spin-off, combination, or exchange of shares), the terms of outstanding awards may not be amended
    to reduce the exercise price of outstanding Options or SARs or cancel outstanding Options or SARS in exchange for cash, other
    awards or Options or SARs with an exercise price that is less than the exercise price of the original Options or SARs without
    stockholder approval.

 

    	 	13	 

    	 	 	 

    

 

	 	(f)	Right
    of Setoff. The Company or any subsidiary may, to the extent permitted by applicable law, deduct from and set off against
    any amounts the Company or its subsidiary may owe to the Participant from time to time, including amounts payable in connection
    with any Award, owed as wages, fringe benefits, or other compensation owed to the Participant, any such amounts as may be
    owed by the Participant to the Company, including but not limited to amounts owed under Section 11(a), although the Participant
    shall remain liable for any part of the Participant’s payment obligation not satisfied through such deduction and setoff.
    By accepting any Award granted hereunder, the Participant agrees to any deduction or setoff under this Section 12(f).
	 	 	 
	 	(g)	Unfunded
    Status of Awards; Creation of Trusts. The Plan is intended to constitute an “unfunded” plan for incentive
    and deferred compensation. With respect to any payments not yet made to a Participant or obligation to deliver Stock pursuant
    to an Award, nothing contained in the Plan or any Award shall give any such Participant any rights that are greater than those
    of a general creditor of the Company; provided that the Committee may authorize the creation of trusts and deposit therein
    cash, Stock, other Awards or other property, or make other arrangements to meet the Company’s obligations under the
    Plan. Such trusts or other arrangements shall be consistent with the “unfunded” status of the Plan unless the
    Committee otherwise determines with the consent of each affected Participant.
	 	 	 
	 	(h)	Nonexclusivity
    of the Plan. Neither the adoption of the Plan by the Board nor its submission to the stockholders of the Company for approval
    shall be construed as creating any limitations on the power of the Board or a committee thereof to adopt such other incentive
    arrangements, apart from the Plan, as it may deem desirable.
	 	 	 
	 	(i)	Payments
    in the Event of Forfeitures; Fractional Shares. Unless otherwise determined by the Committee, in the event of a forfeiture
    of an Award with respect to which a Participant paid cash consideration, the Participant shall be repaid the amount of such
    cash consideration. No fractional shares of Stock shall be issued or delivered pursuant to the Plan or any Award. The Committee
    shall determine whether cash, other Awards or other property shall be issued or paid in lieu of such fractional shares or
    whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.
	 	 	 
	 	(j)	Certain
    Limitations Relating to Accounting Treatment of Awards. At any time that the Company is accounting for stock-denominated
    Awards under the Statement of Financial Accounting Standards No. 123R (“FAS 123R”), the Company intends that,
    with respect to such Awards, the compensation measurement date for accounting purposes shall occur at the date of grant or
    such other date that applies to Awards that are treated as equity awards under FAS 123R, unless the Committee specifically
    determines otherwise. Therefore, other provisions of the Plan notwithstanding, in order to preserve this fundamental objective
    of the Plan, if any authority granted to the Committee hereunder or any provision of the Plan or an Award agreement would
    result, under FAS 123R, in “liability” accounting, if the Committee was not specifically aware of such accounting
    consequence at the time such Award was granted or provision otherwise became effective, such authority shall be limited and
    such provision shall be automatically modified and reformed to the extent necessary to preserve the accounting treatment of
    the award intended by the Committee. This provision shall cease to be effective if and at such time as the Company no longer
    accounts for equity compensation under FAS 123R.

 

    	 	14	 

    	 	 	 

    

 

	 	(k)	Governing
    Law; Jurisdiction. The validity, construction, and effect of the Plan, any rules and regulations relating to the Plan
    and any Award document shall be determined in accordance with the laws of the State of Nevada, without giving effect to principles
    of conflicts of laws, and applicable provisions of federal law. With respect to any suit, action or proceeding (a “Proceeding”)
    arising out of or relating to the Plan each of the Company, each Eligible Person and each Participant hereby irrevocably submits
    to the exclusive jurisdiction of the courts of the state of Washington and the United States of America, in each case located
    in King County, Washington (the “Selected Courts”), and waives any objection to venue being laid in the Selected
    Courts whether based on the grounds of venue, forum non conveniens or otherwise. EACH OF THE FORGOING PARTIES WAIVES, TO THE
    FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT
    IT MAY HAVE TO A TRIAL
    BY JURY IN ANY ACTION, PROCEEDING OR LITIGATION
    DIRECTLY OR INDIRECTLY ARISING OUT
    OF, UNDER OR IN CONNECTION WITH
    THE PLAN OR ANY AWARD
    THEREUNDER.
	 	 	 
	 	(l)	Awards
    to Participants Outside the United States. The Committee may modify the terms of any Award under the Plan made to or held
    by a Participant who is then resident or primarily employed outside of the United States in any manner deemed by the Committee
    to be necessary or appropriate in order that such Award shall conform to laws, regulations, and customs of the country in
    which the Participant is then resident or primarily employed, or so that the value and other benefits of the Award to the
    Participant, as affected by foreign tax laws and other restrictions applicable as a result of the Participant’s residence
    or employment abroad shall be comparable to the value of such an Award to a Participant who is resident or primarily employed
    in the United States. An Award may be modified under this Section 12(l) in a manner that is inconsistent with the express
    terms of the Plan, so long as such modifications will not contravene any applicable law or regulation.
	 	 	 
	 	(m)	Limitation
    on Rights Conferred under Plan. Neither the Plan nor any action taken hereunder shall be construed as (i) giving any Eligible
    Person or Participant the right to continue as an Eligible Person or Participant or in the employ or service of the Company
    or a subsidiary, (ii) interfering in any way with the right of the Company or a subsidiary to terminate any Eligible Person’s
    or Participant’s employment or service at any time, (iii) giving an Eligible Person or Participant any claim to be granted
    any Award under the Plan or to be treated uniformly with other Participants and employees, or (iv) conferring on a Participant
    any of the rights of a stockholder of the Company unless and until the Participant is duly issued or transferred shares of
    Stock in accordance with the terms of an Award or an Option is duly exercised. Except as expressly provided in the Plan and
    an Award document, neither the Plan nor any Award document shall confer on any person other than the Company and the Participant
    any rights or remedies thereunder.
	 	 	 
	 	(n)	Severability;
    Entire Agreement. If any of the provisions of this Plan or any Award document is finally held to be invalid, illegal or
    unenforceable (whether in whole or in part), such provision shall be deemed modified to the extent, but only to the extent,
    of such invalidity, illegality or unenforceability, and the remaining provisions shall not be affected thereby; provided,
    that, if any of such provisions is finally held to be invalid, illegal, or unenforceable because it exceeds the maximum scope
    determined to be acceptable to permit such provision to be enforceable, such provision shall be deemed to be modified to the
    minimum extent necessary to modify such scope in order to make such provision enforceable hereunder. The Plan and any Award
    documents contain the entire agreement of the parties with respect to the subject matter thereof and supersede all prior agreements
    (unless an employment agreement entered into between the Company and the Participant specifically provides contradictory terms,
    in which case the terms of the employment agreement shall govern), promises, covenants, arrangements, communications, representations
    and warranties between them, whether written or oral with respect to the subject matter thereof. In the event of any conflict
    between the terms of this Plan and the terms in an Award Agreement, the terms of the Award Agreement shall control.
	 	 	 
	 	(o)	Termination.
    The Plan is effective as of the Effective Date. Unless earlier terminated by action of the Board of Directors, the Plan
    will remain in effect until such time as no Stock remains available for delivery under the Plan and the Company has no further
    rights or obligations under the Plan with respect to outstanding Awards under the Plan.

 

***

 

    	 	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]